<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>BCSC2017-2018_S08_ch03_p045-078</title>
		<link href="BCSC2017-2018_S08_ch03_p045-078-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC2017-2018_S08_ch03_p045-078" lang="en-US">
		<div id="_idContainer000" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap">Chapter </span><span class="CharOverride-1">3</span></p>
			<p class="chapter-title">Clinical Approach to Ocular Surface Disease</p>
			<p class="h1 ParaOverride-1">Highlights</p>
			<div id="Chapt3_Top1">
			<p class="body-text--no-indent-">
			<ul>
				<li class="bullet-list-first ParaOverride-2">It is helpful both diagnostically and therapeutically to divide dry eye into 2&#160;categories, aqueous tear deficiency (ATD) and evaporative dry eye.</li>
				<li class="bullet-list-mid">Mucous discharge is common in patients with moderate to severe ATD and in patients with infectious conjunctivitis; consequently, ATD is frequently misdiagnosed as infectious conjunctivitis.</li>
				<li class="bullet-list-last ParaOverride-3">Eyelid margin disease is commonly associated with dry eye; effective treatment of eyelid disease is therefore an important adjunct to dry eye management.</li>
			</ul>
			</p>
			</div>
			<p class="h1">Common Clinical Findings in Ocular Surface Disease</p>
			<div id="Chapt3_Top2">
			<p class="body-text--no-indent-">The following sections and tables introduce and define common clinical findings of the external eye and cornea that aid in the diagnosis of ocular surface disease (<span class="xref-table">Table&#160;3-1</span>).</p>
			<p class="h2">Conjunctival Signs</p>
			<p class="body-text--no-indent-"><span class="xref-table">Table&#160;3-2</span> lists conjunctival findings, with examples of ocular and systemic conditions in which they are seen.</p>
			<p class="h3">Papillae</p>
			<p class="body-text--no-indent-">Papillae are vascular changes seen most easily in the palpebral conjunctiva where fibrous septa anchor the conjunctiva to the tarsus. With progression, these dilated vessels sprout spokelike capillaries that become surrounded by edema and a mixed inflammatory cell infiltrate, producing raised elevations under the conjunctival epithelium (<span class="xref-figure">Fig&#160;3-1</span>).</p>
			<p class="body-text">A mild papillary reaction produces a smooth, velvety appearance (<span class="xref-figure">Fig&#160;3-2A</span>). Chronic or progressive changes result in enlarged vascular tufts that obscure the underlying blood vessels (Fig&#160;3-2B). Connective tissue septa restrict inflammatory changes to the fibrovascular core, producing the appearance of elevated, polygonal, hyperemic mounds. Each papilla has a central red dot that represents a dilated capillary viewed end-on. Examination of the palpebral, bulbar, and forniceal conjunctivae beyond the tarsus is less helpful in revealing the nature of an inflammatory reaction, because the anchoring septa become sparser toward the fornix and permit undulation of less adherent tissue. With prolonged, recurrent, or severe conjunctival inflammation, the anchoring fibers of the tarsal conjunctiva stretch and weaken, leading to confluent papillary hypertrophy. <span class="italic">Giant papillae</span> are defined as those with a diameter greater than 0.3&#160;mm (Fig&#160;3-2C). The furrows between these enlarged fibrovascular structures collect mucus and purulent material. After treatment, a fibrotic subepithelial scar may be seen at the apex of the former giant papilla.</p>
			<p class="h3 ParaOverride-4">Follicles</p>
			<p class="body-text--no-indent-">Conjunctival lymphoid tissue is normally present within the substantia propria except in neonates, who do not have visible follicles. Conjunctival follicles are round or oval clusters of lymphocytes (<span class="xref-figure">Fig&#160;3-3</span>). Small follicles are often visible in the normal lower fornix. Clusters of enlarged, noninflamed follicles are occasionally seen in the forniceal or inferior palpebral conjunctiva of children and adolescents, a condition known as <span class="italic">benign lymphoid folliculosis</span> (<span class="xref-figure">Fig&#160;3-4</span>).</p>
			<p class="body-text">Follicular conjunctivitis is characterized by conjunctival injection and the presence of new or enlarged follicles (<span class="xref-figure">Fig&#160;3-5</span>). Vessels surround and encroach on the raised surface of follicles but are not prominently visible within the follicle. Follicles can be seen in the inferior and superior tarsal conjunctiva and, less often, on the bulbar or limbal conjunctiva. They must be differentiated from cysts produced by tubular epithelial infoldings during chronic inflammation and lymphangiectasis.</p>
			<p class="body-text">See also BCSC Section&#160;4, <span class="italic">Ophthalmic Pathology and Intraocular Tumors.</span></p>
			<p class="reference-single ParaOverride-5">Stern G. Chronic conjunctivitis, Parts&#160;1–2. <span class="italic">Focal Points: Clinical Modules for Ophthal&#173;mologists.</span> San Francisco: American Academy of Ophthalmology; 2012, modules 11–12.</p>
			<p class="h2 ParaOverride-6">Corneal Signs</p>
			<p class="body-text--no-indent-">Corneal signs of inflammation are described in <span class="xref-table">Table&#160;3-3</span>. The pattern of corneal inflammation, or <span class="italic">keratitis,</span> can be described according to the following:</p>
			<ul>
				<li class="bullet-list-first ParaOverride-7"><span class="italic">distribution:</span> diffuse, focal, or multifocal</li>
				<li class="bullet-list-mid"><span class="italic">depth:</span> epithelial, subepithelial, stromal, or endothelial</li>
				<li class="bullet-list-mid"><span class="italic">location:</span> central, paracentral, or peripheral</li>
				<li class="bullet-list-last ParaOverride-8"><span class="italic">shape:</span> dendritic, disciform, and so on</li>
			</ul>
			<p class="body-text--no-indent-">The clinician should also note any structural or physiologic changes associated with keratitis, such as ulceration or endothelial dysfunction.</p>
			<p class="body-text">Punctate epithelial keratitis (PEK) is a nonspecific term that encompasses a spectrum of biomicroscopic changes, from punctate epithelial granularity to erosive and inflammatory changes (<span class="xref-figure">Fig&#160;3-6</span>). Punctate epithelial erosions (PEE) are lesions of abnormal or degenerated corneal epithelial cells that stain with fluorescein.</p>
			<p class="body-text">Inflammatory cells can enter the stroma from the tear film, through an epithelial defect; less often, they enter by direct interlamellar infiltration of leukocytes at the limbus (eg, after laser in situ keratomileusis [LASIK]). In the presence of endothelial injury, inflammatory cells enter from aqueous humor. Stromal inflammation may be manifested by the presence of new blood vessels. In a vascularized cornea, inflammatory cells can enter the stroma directly from infiltrating blood and lymphatic vessels.</p>
			<p class="body-text">Stromal inflammation is characterized as <span class="italic">suppurative</span> or <span class="italic">nonsuppurative</span> (<span class="xref-figure">Fig&#160;3-7</span>). It is further described by distribution (<span class="italic">focal</span> or <span class="italic">multifocal</span> infiltrates) and by location (<span class="italic">central, paracentral,</span> or <span class="italic">peripheral</span>). The differential diagnosis for suppurative corneal inflammation or necrotizing stromal keratitis includes microbial keratitis due to bacteria, fungi, or acanthamoeba; retained foreign body; and topical anesthetic abuse. Nonsuppurative stromal keratitis can be caused by reactive arthritis, Cogan syndrome, viral keratitis, congenital or acquired syphilis, Lyme disease, tuberculosis, leprosy (Hansen disease), and onchocerciasis.</p>
			<p class="body-text">Endothelial dysfunction often leads to epithelial and stromal edema. Swollen endothelial cells called <span class="italic">inflammatory pseudoguttae</span> are visible by specular reflection as dark areas of the normal endothelial mosaic pattern. <span class="italic">Keratic precipitates (KPs)</span> are clumps of inflammatory cells that adhere to the back of the cornea and come from the anterior uvea during the course of keratitis or uveitis. The clinical appearance of KPs depends on their composition:</p>
			<ul>
				<li class="bullet-list-first">Fibrin and other proteins coagulate into small dots and strands.</li>
				<li class="bullet-list-mid">Neutrophils and lymphocytes aggregate into punctate opacities.</li>
				<li class="bullet-list-last">Macrophages form larger “mutton-&#173;fat” clumps.</li>
			</ul>
			<p class="body-text">Corneal inflammation can lead to opacification. Altered stromal keratocytes fail to produce some water-&#173;soluble factors and, consequently, make new collagen fibers that are disorganized, scatter light, and form a nontransparent scar. Scarring can incorporate calcium complexes, lipids, and proteinaceous material. Dark pigmentation of a residual corneal opacity is often a result of incorporated melanin or iron salts.</p>
			<p class="body-text">Corneal inflammation can also lead to neovascularization. Superficial stromal blood vessels originate as capillary buds of limbal vascular arcades in the palisades of Vogt. New lymphatic vessels may also form but cannot be seen clinically. Subepithelial fibrous ingrowth into the peripheral cornea is called a <span class="italic">pannus</span> or <span class="italic">vascularized pannus</span> (<span class="xref-figure">Fig&#160;3-8</span>). Neovascularization may invade the cornea at deeper levels depending on the nature and location of the inflammatory stimulus.</p>
			<p class="reference-first">Ciralsky J, Lai E, Waring GO III, Bouchard CS. A matrix of pathologic responses in the cornea. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol 1. 4th ed. Philadelphia: Elsevier; 2017:46–71. </p>
			<p class="reference-last--no-space-">Leibowitz HM, Waring GO III, eds. <span class="italic">Corneal Disorders: Clinical Diagnosis and Management.</span> 2nd&#160;ed. Philadelphia: Saunders; 1998:432–479.</p>
			</div>
			<p class="h1">Clinical Approach to Dry Eye</p>
			<div id="Chapt3_Top3">
			<p class="body-text--no-indent-">In 2007, the International Dry Eye Workshop defined <span class="italic">dry eye</span> as “a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface.” Dry eye represents a disturbance of the lacrimal functional unit, an integrated system comprising the lacrimal glands, ocular surface (cornea, conjunctiva, and limbus), and eyelids, as well as the sensory and motor nerves connecting these components. See Chapter&#160;1 for a discussion and illustration of the lacrimal functional unit.</p>
			<p class="body-text">Dry eye is one of the most common reasons for ophthalmic consultation. It becomes increasingly prevalent with age, affecting approximately 10% of individuals 30–60&#160;years of age and 15% of adults older than 65&#160;years. Most epidemiologic studies have demonstrated a higher prevalence among women; dry eye seems to affect all racial and ethnic groups equally.</p>
			<p class="body-text">The psychological problems associated with a highly symptomatic, incurable, chronic disease can require considerable support. Results of quality-&#173;of-life studies have shown that the impact of moderate to severe dry eye on affected patients is similar to that of moderate to severe angina. Organizations such as the Sjögren’s Syndrome Foundation (www<br />.sjogrens.org) can provide valuable resources for these patients. For certain patients, consultation with physicians who specialize in pain management can be very helpful.</p>
			<p class="reference-single ParaOverride-9">The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). <span class="italic">Ocul Surf.</span> 2007;5(2):75–92.</p>
			<p class="h2">Mechanisms of Dry Eye</p>
			<p class="body-text--no-indent-">Dry eye results from a combination of factors. Tear hyperosmolarity stresses the surface epithelium and leads to the release of inflammatory mediators, which disrupt the junctions between the superficial epithelial cells. T&#160;cells can then infiltrate the epithelium and in turn produce cytokines such as tumor necrosis factor-<span class="greek--tx-">a</span> and interleukin-1. These cytokines promote accelerated detachment of the epithelial cells and apoptosis (programmed cell death). This results in further disruption of junctions and influx of inflammatory cells, creating a vicious cycle. The cycle of events is shown in <span class="xref-figure">Figure&#160;3-9</span>.</p>
			<p class="body-text">One diagnostic classification scheme divides dry eye patients into those with aqueous tear deficiency and those with evaporative dry eye (<span class="xref-figure">Fig&#160;3-10</span>). An individual patient may have elements of both conditions, however. In aqueous tear deficiency, T-cell–mediated inflammation of the lacrimal gland occurs, leading to diminished tear production and the propagation of inflammatory mediators on the ocular surface. In evaporative dry eye, the primary abnormality is meibomian gland dysfunction, in which altered lipid metabolism of the meibum causes a transition from unsaturated to saturated fats, resulting in obstruction of the glands. This leads to tear film instability as well as tear evaporation and hyperosmolarity, initiating the inflammatory cycle.</p>
			<p class="body-text">Tear film instability can also be initiated by other conditions, including xerophthalmia, ocular allergy, contact lens wear, a high ratio of dietary n-6 to n-3 essential fatty acids, diabetes mellitus, cigarette smoking, prolonged use of video displays, and long-term use of medications with topical preservatives such as benzalkonium chloride.</p>
			<p class="body-text">Epithelial injury stimulates corneal nerve endings, leading to symptoms such as ocular discomfort, increased blinking, and, potentially, compensatory reflex lacrimal tear secretion. Loss of normal mucins at the ocular surface contributes to symptoms by increasing frictional resistance between the eyelids and globe. During this period of corneal nerve stimulation, the high reflex input may cause neurogenic inflammation within the lacrimal gland.</p>
			<p class="body-text">Tear delivery may be obstructed by cicatricial conjunctival scarring or reduced by a loss of sensory reflex drive to the lacrimal gland from the ocular surface. The etiology of dry eye may include refractive surgery (eg, LASIK), contact lens wear, and chronic topical anesthetic abuse. The pathogenesis of dry eye may involve several interacting mechanisms.</p>
			<p class="reference-first ParaOverride-10">American Academy of Ophthalmology Cornea/External Disease Panel. Preferred&#160;Practice Pattern Guidelines. <span class="italic">Dry Eye Syndrome.</span> San Francisco: American Academy of Ophthalmology; 2013. Available at www.aao.org/ppp.</p>
			<p class="reference-mid">The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). <span class="italic">Ocul Surf.</span> 2007;5(2):75–92.</p>
			<p class="reference-mid">Bohm KJ, Djalilian AR, Pflugfelder SC, Starr CE. Dry eye. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol 1. 4th ed. Philadelphia: Elsevier; 2017:377–396.</p>
			<p class="reference-mid">Nichols KK, Foulks GN, Bron AJ, et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. <span class="italic">Invest Ophthalmol Vis Sci.</span> 2011;52(4):1922–1929.</p>
			<p class="reference-mid">Pflugfelder SC. Tear dysfunction and the cornea: LXVIII Edward Jackson Memorial Lecture. <span class="italic">Am&#160;J Ophthalmol.</span> 2011;152(6):900–909.</p>
			<p class="reference-last ParaOverride-9">Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-&#173;mediated ocular surface disorder. <span class="italic">Arch Ophthalmol.</span> 2012;130(1):90–100.</p>
			<p class="h2 ParaOverride-11">Aqueous Tear Deficiency</p>
			<p class="body-text--no-indent-">The clinical presentation of aqueous tear deficiency (ATD) ranges from mild ocular irritation with minimal ocular surface disease to severe and disabling disease. Patients commonly report burning, a dry sensation, photophobia, and blurred vision. Symptoms tend to be worse toward the end of the day, with prolonged use of the eyes (exacerbated by the reduced blink rate associated with computer use), or with exposure to environmental extremes (eg, lower levels of humidity associated with indoor heating or air conditioning). The clinician can quickly assess dry eye by conducting the “stare test”: after a few blinks, the patient is asked to look at a visual acuity chart; the time until the image blurs should be more than 8&#160;seconds.</p>
			<p class="body-text">Signs of ATD include bulbar conjunctival hyperemia, a decreased tear meniscus, an irregular corneal surface, and debris in the tear film. Slit-lamp examination of the inferior tear meniscus (which is normally 1.0&#160;mm in height and convex) is an additional, important evaluation. A significantly reduced tear meniscus is considered abnormal. Epithelial keratopathy, which can be fine and granular, coarse, or confluent, is best demonstrated following the instillation of lissamine green, rose bengal, or fluorescein dye. Rose bengal and lissamine green staining can be more sensitive than fluorescein staining in revealing early or mild cases of keratoconjunctivitis sicca (KCS) because they stain devitalized epithelium. The staining may be seen at the nasal and temporal limbus and/or inferior paracentral cornea <span class="italic">(exposure staining).</span> Mucous discharge is common in patients with moderate to severe ATD and in those with infectious conjunctivitis; consequently, ATD is frequently misdiagnosed as infectious conjunctivitis.</p>
			<p class="body-text">In severe ATD, filaments (strands of degenerating epithelial cells attached to the corneal surface over a core of mucus) and mucous plaques may be seen. Filamentary keratopathy can be quite painful, as these strands are firmly attached to the richly innervated surface epithelium (<span class="xref-figure">Fig&#160;3-11</span>). Marginal or paracentral corneal thinning and even perforation can occur in severe dry eye. Incomplete blinking is frequently noted. Advanced disease may also involve corneal calcification (band keratopathy), particularly in association with certain topical medications (especially glaucoma medications), and keratini&#173;zation of the cornea and conjunctiva. A grading scheme for dry eye severity is presented in <span class="xref-table">Table&#160;3-4</span>. See Chapter 2 for a discussion on tear production evaluation and tear film quantitative tests.</p>
			<p class="h3 ParaOverride-6">Sjögren syndrome</p>
			<p class="body-text--no-indent-">Patients with ATD are considered to have Sjögren syndrome if they have associated hypergammaglobulinemia, collagen vascular disease, or circulating autoantibodies (eg, SS-A, SS-B). The revised international classification criteria for Sjögren syndrome appear in <span class="xref-table">Table&#160;3-5</span>. Although the precise causes of ATD in Sjögren syndrome are unknown, ATD is generally considered to be a T-cell–mediated inflammatory disease leading to destruction of the lacrimal glands, in part by increasing the rate of programmed cell death.</p>
			<p class="body-text">Involvement of the salivary glands is common in Sjögren syndrome, resulting in dry mouth and predisposing the patient to periodontal disease. Mucous membranes throughout the body (ie, vaginal, gastric, and respiratory mucosae) may also be affected, which would have a great impact on the patient’s quality of life.</p>
			<p class="body-text">Sjögren syndrome can be divided into 2&#160;clinical subsets. In primary Sjögren syndrome, patients either have ill-&#173;defined systemic immune dysfunction or lack any evidence of immune dysfunction or connective tissue disease. In secondary Sjögren syndrome, patients have a well-&#173;defined, generalized connective tissue disease, most commonly rheumatoid arthritis; however, many other autoimmune and systemic diseases are associated with secondary Sjögren syndrome (<span class="xref-table">Table&#160;3-6</span>).</p>
			<p class="h2 ParaOverride-12">Evaporative Dry Eye</p>
			<p class="body-text--no-indent-">The symptoms in evaporative dry eye consist of burning, foreign-&#173;body sensation, redness of the eyelids and conjunctiva, and filmy vision that is worse in the morning. The clinical signs associated with evaporative disease are usually confined to the posterior eyelid margins, although patients may occasionally have associated seborrheic changes on the anterior eyelid margin. The posterior eyelid margins are often irregular and have prominent, telangiectatic blood vessels coursing from the posterior to anterior eyelid margins. The meibomian gland orifices may pout or show metaplasia, with white material extending through the glandular orifice (<span class="xref-figure">Fig&#160;3-12</span>). They also may become posteriorly displaced on the eyelid margin. In active disease, meibomian secretions may be turbid, more viscous, or even cheesy.</p>
			<p class="body-text">As discussed, the primary abnormality in evaporative dry eye is meibomian gland dysfunction (MGD), which the International Workshop on Meibomian Gland Dysfunction has classified as high delivery (ie, hypersecretory) or low delivery. Low delivery is further divided into hyposecretory or obstructive. Obstructive MGD can be cicatricial (eg, trachoma, mucous membrane pemphigoid, or atopy), or noncicatricial (eg, seborrheic dermatitis, rosacea, or atopy). MGD is more common in people of Asian ethnicity than it is in whites.</p>
			<p class="body-text">Occasionally, a patient is symptomatic but lacks obvious clinical signs of meibomian disease. The meibomian glands appear normal; however, with mild compression, obstruction of the glands is detected. More forceful expression produces a thin filamentous secretion, which is due to narrowing of the distal portion of the ducts, near the orifice. This condition is believed to be a precursor to clinically apparent disease. Expression of the glands can be performed using a cotton swab or a commercially available handheld device.</p>
			<p class="body-text">Extensive atrophy of the meibomian gland acini may develop after years of inflammation from MGD, so that eyelid compression does not result in expression of meibomian gland secretions. Atrophy of meibomian gland acini and derangement of glandular architecture can be demonstrated by shortening or absence of the vertical lines of the meibomian glands, which may be revealed by transillumination of the everted eyelid using a muscle light or infrared photography (see Chapter&#160;2).</p>
			<p class="body-text">Tear breakup is a functional measure of tear film stability. In MGD, the stability is disrupted, causing a rapid tear breakup time (TBUT). After a fluorescein strip moistened with sterile saline has been applied to the tarsal conjunctiva, the tear film is evaluated using a broad beam of the slit lamp with cobalt blue illumination. This should be done before any manipulation of the eyelids or instillation of other drops. Fluorescein-&#173;anesthetic combination drops are not recommended for this purpose, because excessive fluorescein is typically instilled and the anesthetic may affect the ocular surface. The time lapse between the last blink and the appearance of the first randomly distributed dry spot on the cornea is the TBUT. The appearance of dry spots in less than 10&#160;seconds is considered abnormal.</p>
			<p class="body-text">Additional clinical findings in MGD include foam in the tear meniscus along the lower eyelid, bulbar and tarsal conjunctival injection, papillary reaction on the inferior tarsus, linear staining along the inferior cornea and inferior conjunctiva, episcleritis, marginal epithelial and subepithelial infiltrates, corneal neovascularization or pannus, and corneal scarring or thinning. Corneal vascularization is more typical of MGD, while punctate staining is more typical of staphylococcal blepharitis.</p>
			<p class="body-text">Patients with MGD frequently have acne rosacea. Rosacea is discussed later in this chapter.</p>
			<p class="reference-first">American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. <span class="italic">Blepharitis.</span> San Francisco: American Academy of Ophthalmology; 2013. Available at www.aao.org/ppp.</p>
			<p class="reference-last--no-space-">Foulks GN. Meibomian gland dysfunction. <span class="italic">Focal Points: Clinical Modules for Ophthalmologists.</span> San Francisco: American Academy of Ophthalmology; 2014, module&#160;12.</p>
			<p class="h2">Treatment of Dry Eye</p>
			<p class="body-text--no-indent-">Before treatment of dry eye is initiated, the eye should be carefully examined for conjunctivochalasis, floppy eyelid syndrome, superior limbic keratoconjunctivitis, nighttime lagophthalmos, and other structural and exogenous disorders that can cause symptoms similar to those of dry eye. In addition, the clinician must determine whether the patient has any associated systemic conditions (eg, Parkinson disease or mucous membrane pemphigoid) or uses medications that can contribute to dry eye, such as drugs with antihistaminic or anticholinergic properties (see “Medical management of aqueous tear deficiency”).</p>
			<p class="body-text">ATD and evaporative dry eye frequently coexist. Certain therapeutic interventions, such as artificial tear supplements, topical cyclosporine, short pulses of topical corticosteroids, and omega-3 fatty acid supplements, are helpful for both conditions. However, certain treatments for ATD can exacerbate evaporative dry eye. For example, punctal occlusion in the presence of active MGD increases the retention of the toxic meibum secretions.</p>
			<p class="h3 ParaOverride-4">Medical management of aqueous tear deficiency</p>
			<p class="body-text--no-indent-">Selection of the treatment modalities for patients with ATD depends largely on the severity of their disease (<span class="xref-table">Table&#160;3-7</span>). Since smoking is a risk factor for dry eye, advice should be given regarding cessation. It may also be appropriate to modify the patient’s environment in an effort to reduce evaporation of the tear film; a humidifier and/or moisture shields on glasses can be helpful in severe cases.</p>
			<p class="body-text">Changing or discontinuing any topical or systemic medications that may contribute to the condition should be considered, although this is not always practical. Topical <br />β-&#173;blockers have been associated with an increased incidence of dry eye, and many systemic medications (diuretics, antihistamines, and anticholinergic and psychotropic drugs) decrease aqueous tear production and increase dry eye symptoms. These drugs should be avoided as much as possible in patients with symptoms of ATD (<span class="xref-table">Table&#160;3-8</span>).</p>
			<p class="body-text">The mainstay of treatment for ATD is the use of tear substitutes (drops, gels, and ointments). Preservative-&#173;free tear substitutes are recommended to avoid the toxic effects that can arise with dosing more than 4&#160;times daily. Demulcents are polymers added to artificial tear solutions to improve their lubricant properties. Demulcent solutions are mucomimetic agents that can briefly substitute for glycoproteins lost late in the disease process. Demulcents alone, however, cannot restore lost glycoproteins or conjunctival goblet cells, reduce corneal cell desquamation, or decrease tear film osmolarity. Until relatively recently, all demulcent solutions contained preservatives. Preservative-&#173;free demulcent solutions were introduced after it was recognized that preservatives increase corneal desquamation. The elimination of preservatives from traditional demulcent solutions has led to improved corneal barrier function in patients using these agents, and subsequent attempts have been made to improve function even further by adding various ions to the solutions. Liposomal sprays, applied to the closed eyelids by a sterile spray mechanism, may help support the tear film. Hydroxypropyl cellulose inserts are occasionally helpful for patients unable to frequently instill artificial tears.</p>
			<p class="body-text">Topical cyclosporine A 0.05% addresses the inflammatory component of moderate to severe ATD and is thus being used earlier in the disease course. Therapy is often initiated in combination with a short course of topical corticosteroids to provide an initial reduction in surface inflammation. Patients should be advised that it may take many months of consistent twice-&#173;daily use before they obtain symptomatic relief, which results from the anti-&#173;inflammatory benefits of cyclosporine. Also, they should be informed that in moderate to severe ATD, the percentage of patients that seem to benefit from topical cyclo&#173;spor&#173;ine may be only 50%. While some patients experience stinging upon instillation, adverse effects are generally minimal. Refrigeration of the medication may help reduce this symptom. Additional agents that prevent T-cell–mediated inflammation are currently being investigated.</p>
			<p class="body-text">Other treatments that have been successful in patients with severe ATD are dilute solutions of hyaluronic acid and autologous serum drops. The composition of diluted autologous serum is somewhat similar to that of normal tears, particularly in regard to growth factors; therefore, some of the benefit may relate to the trophic function of these substances. Autologous serum drops require blood draws of 3 or 4&#160;red-top tubes. The tubes are spun to separate the serum; they are then placed on dry ice and sent to a compounding pharmacy, which prepares the solution for the patient. Besides its use in the treatment of ATD, autologous serum may be helpful for patients with persistent epithelial defects and neurotrophic keratopathy.</p>
			<p class="body-text">Treatment of filamentary keratopathy associated with severe ATD can be challenging. Filaments should be debrided with a jeweler’s forceps or a cotton swab soaked with topical anesthetic. Treatment directed at enhancing the tear film reduces the severity of recurrence. In addition to tear supplementation and punctal occlusion, acetylcysteine 10%, dispensed with an eyedrop container, can serve as a mucolytic agent and may further reduce filament formation. Topical low-dose corticosteroids, cyclosporine, and therapeutic soft contact lenses may be helpful. While therapeutic soft contact lenses may be beneficial for treatment of filamentary keratitis due to other causes, bandage soft contact lenses are rarely used to reduce symptoms in patients with ATD, because they may be associated with an increased risk of infection. Patients who use them should therefore be observed carefully. Scleral contact lenses have been found to be extremely helpful in patients with advanced dry eye symptoms.</p>
			<p class="body-text">In severe cases of ATD, use of moisture-&#173;retaining eyewear, also called moisture chamber glasses (glasses, goggles, or sunglasses incorporating a moisture shield or seal), can decrease tear evaporation; however, all but the most severely affected patients may find this therapy cosmetically objectionable.</p>
			<p class="body-text">Pharmacologic stimulation of tear secretion has been attempted using many compounds, with varying degrees of success. The cholinergic agonists pilocarpine and cevimeline hydrochloride stimulate muscarinic receptors present in salivary and lacrimal glands, thereby increasing secretion. Although studies have shown the 2&#160;agents to be effective in treating both xerostomia and dry eye in patients with Sjögren syndrome, they are approved by the US Food and Drug Administration (FDA) only for the treatment of xerostomia. It is uncertain whether these agents provide long-term benefits, and they are associated with significant adverse effects, which may affect patient adherence.</p>
			<p class="body-text">Dietary supplementation with omega-3 fatty acids has been shown to increase average tear production and tear volume. Certain fish (eg, salmon, tuna, cod, flounder) and crustaceans (shrimp and crab), flaxseed oil, dark leafy greens, and walnuts are rich in omega-3 fatty acids, which block proinflammatory eicosanoids and cytokines. Commercial preparations of omega-3 fatty acids are also available and include TheraTears Eye Nutrition (Akorn Consumer Health, Lake Forest, IL), Dry Eye Omega Benefits (PRN Physician Recommended Nutriceuticals, Plymouth Meeting, PA), HydroEye (ScienceBased Health, Houston, TX), and Systane Vitamin (Alcon, Fort Worth, TX).</p>
			<p class="reference-first">Epitropoulos AT, Donnenfeld ED, Shah ZA, et al. Effect of oral re-&#173;esterified omega-3 nutritional supplementation on dry eyes. <span class="italic">Cornea.</span> 2016;35(9):1185–1191.</p>
			<p class="reference-mid">Kojima T, Higuchi A, Goto E, Matsumoto Y, Dogru M, Tsubota K. Autologous serum eye drops for the treatment of dry eye diseases. <span class="italic">Cornea.</span> 2008;27(Suppl&#160;1):S25–S30.</p>
			<p class="reference-last--no-space-">Wojtowicz JC, Butovich I, Uchiyama E, Aronowicz J, Agee S, McCulley JP. Pilot, prospective, randomized, double-&#173;masked, placebo-&#173;controlled clinical trial of an omega-3 supplement for dry eye. <span class="italic">Cornea.</span> 2011;30(3):308–314.</p>
			<p class="h3">Surgical management of aqueous tear deficiency</p>
			<p class="body-text--no-indent-">Surgical treatment is generally reserved for patients with severe disease for whom medical treatment is either inadequate or impractical. Patients with moderate to severe ATD may benefit from punctal occlusion, which can be temporary, semipermanent, or permanent. Reversible punctal occlusion can be performed using collagen implants or silicone punctal plugs and has varying degrees of effectiveness (<span class="xref-figure">Fig&#160;3-13</span>). Collagen plugs usually dissolve within days and do not provide complete canalicular occlusion. Intracanalicular plugs made of polydioxanone (eg, VisiPlug; Lacrimedics Inc, Eastsound, WA) provide occlusion for up to 6&#160;months. These plugs can be seen by transilluminating the eyelid, enabling the clinician to determine whether they have become displaced or eroded. The Extend plug, another absorbable implant (Beaver-&#173;Visitec International, Waltham, MA), dissolves over a 3-month period. Permanent intracanalicular plugs have been associated with infectious canaliculitis and sterile inflammation, which in some cases have required canaliculotomy and dacryocystorhinostomy. The absorbable intracanalicular plugs may be less likely to cause such problems; however, clinicians should be aware of the risk of intracanalicular inflammation.</p>
			<p class="body-text">Silicone plugs may remain in place for months or years unless they are inadequately sized or are manually displaced. For example, Parasol plugs (Beaver-&#173;Visitec International) have a high retention rate. Some plugs have a small hole bored through the center to reduce the likelihood of epiphora. Most silicone plugs are continuously visible at the slit lamp, making it obvious if they become displaced or eroded.</p>
			<p class="body-text">If inserted too forcefully, punctal plugs can be inadvertently inserted into the canaliculus and may require surgical removal. If a plug protrudes from the punctum, conjunctival irritation or abrasion may occur. Granuloma formation at the punctal opening has been seen and may require removal of the plug and possible excision.</p>
			<p class="body-text">The most cost-&#173;effective manner of performing irreversible punctal occlusion is with a disposable cautery, a hyfrecator, or a radiofrequency probe. Although the procedure is usually permanent, the canaliculi and puncta may subsequently recanalize.</p>
			<p class="body-text">The value of punctal occlusion for ocular surface disease other than tear deficiency is unproven. The procedure is recommended primarily for patients who have minimal basal tear secretion and punctate keratopathy but no significant ocular surface inflammation or infection. Correction of eyelid malpositions such as entropion and ectropion may also be beneficial in managing patients with dry eye symptoms. Reduction of the palpebral aperture by means of lateral and/or medial tarsorrhaphy can be performed in severe KCS when more conservative measures have failed. However, lateral tarsorrhaphy may limit the temporal visual field and produce an undesirable cosmetic deformity.</p>
			<p class="reference-first">American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. <span class="italic">Dry Eye Syndrome.</span> San Francisco: American Academy of Ophthalmology; 2013. Available at www.aao.org/ppp.</p>
			<p class="reference-mid">The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. <span class="italic">Ocul Surf.</span> 2007;5(2):75–92.</p>
			<p class="reference-mid">Marcet MM, Shtein RM, Bradley EA. Safety and efficacy of lacrimal drainage system plugs for dry eye syndrome: a report by the American Academy of Ophthalmology. <span class="italic">Ophthalmology.</span> 2015;122(8):1681–1687.</p>
			<p class="reference-mid">Mazow ML, McCall T, Prager TC. Lodged intracanalicular plugs as a cause of lacrimal obstruction. <span class="italic">Ophthal Plast Reconstr Surg.</span> 2007;23(2):138–142.</p>
			<p class="reference-last--no-space-">Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-&#173;mediated ocular surface disorder. <span class="italic">Arch Ophthalmol.</span> 2012;130(1):90–100.</p>
			<p class="h3">Medical management of evaporative dry eye</p>
			<p class="body-text--no-indent-">Management is based on the stage of MGD; see <span class="xref-table">Tables&#160;3-9 and 3-10</span>. Eyelid hygiene is the mainstay of treatment. Application of warm compresses to the eyelids twice daily for 3–5&#160;minutes liquefies thickened meibomian gland secretions and softens adherent crusts on the eyelid margins. The patient should be warned to avoid excessive or uneven heat if a microwave is used for the compress. The application of heat should be followed by moderate to firm massage of the eyelids to express retained meibomian secretions. Eyelid massage can be followed by cleansing of the closed eyelid margin with a clean washcloth or a commercially available pad. A solution prepared with a nonirritating shampoo and water or a commercially available solution designed for this purpose may facilitate cleansing.</p>
			<p class="body-text">Short-term or periodic use of topical antibiotics reduces the bacterial load on the eyelid margin. Topical azithromycin ophthalmic solution may be particularly efficacious, as it is a lipophilic antibiotic that reduces the production of bacterial lipases and improves the composition of meibomian lipids. The high viscosity of the drop prolongs the contact time and aids its penetration into the glands. Long-term use of topical antibiotics or subtherapeutic dosing can result in the development of resistant organisms.</p>
			<p class="body-text">Topical corticosteroids may be required for short periods in cases with moderate to severe inflammation, particularly if corneal infiltrates and vascularization are present. Patients treated with topical corticosteroids should be warned about the potential complications associated with long-term use.</p>
			<p class="body-text">Patients with blepharitis and obstructive MGD benefit from dietary changes and omega-3 supplementation. In one study, the use of 1000-mg omega-3 nutritional supplements 3&#160;times a day for 1&#160;year was found to improve symptoms, tear film stability, and meibomian secretions. In another study, supplementation with fish oil showed no significant effect on meibum lipid composition or aqueous tear evaporation rate, but average tear production and tear volume increased. Therefore, the mechanism of action of omega-3 supplementation for MGD is not yet established.</p>
			<p class="body-text">Treatment with oral tetracyclines can be very effective; however, patients with MGD should be informed that therapy may only control their condition, not eliminate it. Because tetracycline must be taken on an empty stomach and requires more frequent dosing, doxycycline and minocycline are increasingly used. The dosages for doxycycline and minocycline are 100&#160;mg and 50&#160;mg, respectively, every 12&#160;hours for 1–2&#160;weeks; the dose for each drug is tapered to 50&#160;mg daily. Even lower doses may be equally effective. Therapy must often be repeated to achieve long-term control. If long-term therapy is required, a 1-week structured treatment interruption each month may reduce the risk of yeast infection. Erythromycin can be used as alternative therapy in children or in patients with known hypersensitivity to tetracycline.</p>
			<p class="body-text">Adverse effects of oral tetracyclines include photosensitization, gastrointestinal upset, and, in rare instances, azotemia. Long-term use may lead to oral or vaginal candidiasis in susceptible patients. The use of tetracyclines is contraindicated during pregnancy, in women who are breastfeeding, and in patients with a known hypersensitivity to these agents. These agents should be used with caution in women of childbearing age, women with a family history of breast cancer, and patients with a history of liver disease. Oral tetracyclines can also potentiate the effect of certain anticoagulants (eg, warfarin). In addition, these antibiotics should be avoided in children younger than 8&#160;years because they cause permanent discoloration of teeth and bones in this population. Tetracyclines may reduce the efficacy of oral contraceptives. Oral azithromycin is an alternative treatment, but it may be hazardous when used in patients with cardiovascular problems. In March 2013, the FDA issued a warning that oral azithromycin may lead to abnormalities in the electrical activity of the heart, with the potential to create serious irregularities in heart rhythm.</p>
			<p class="body-text">Recently, several new modalities have been introduced for the treatment of MGD. Mechanical meibomian gland probing using special instruments (Maskin Meibomian Gland Intraductal Probe; Rhein Medical Inc, St Petersburg, FL) lyses a fibrovascular membrane growing into the duct and may facilitate gland function, permitting normal secretion of meibum. The LipiFlow thermal pulsation system (TearScience, Morrisville, NC), which combines gentle pulsatile pressure and thermal energy to increase blood flow to the eyelid and open obstructed meibomian gland ductules, may be an appropriate alternative when conventional treatment has failed to improve symptoms. Variable improvement in dry eye symptoms has been achieved with this treatment modality; however, it is expensive and may need to be repeated. Adverse effects of LipiFlow, which are self-&#173;limited, include conjunctival hyperemia, edema, hemorrhage, and surface staining. The safety and efficacy of LipiFlow have not been established in moderate to severe allergic or vernal conjunctivitis, in the presence of severe eyelid inflammation, or for dry eye related to systemic disease. LipiFlow should not be used in the presence of active infection, postoperatively, or in the presence of functional abnormalities of the eyelid. The MiBoFlo Thermoflo (Mibo Medical Group, Dallas, TX) utilizes a thermoelectric heat pump to promote liquefaction of meibum; the device is applied to the eyelid skin manually, supplying continuous heat. Intense pulsed-&#173;light (IPL) therapy (Lumenis, San Jose, CA), a concentrated heat treatment, may also be used to treat MGD. The efficacy of these treatments has not been proven in well-&#173;designed, prospective, randomized, controlled studies.</p>
			<p class="reference-first ParaOverride-13">American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. <span class="italic">Blepharitis.</span> San Francisco: American Academy of Ophthalmology; 2013. Available at www.aao.org/ppp.</p>
			<p class="reference-mid">Foulks GN, Lemp MA. Meibomian gland dysfunction and seborrhea. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol 1. 4th ed. Philadelphia: Elsevier; 2017:357–365.</p>
			<p class="reference-last--no-space-">Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction. <span class="italic">Trans Am Ophthalmol Soc.</span> 2008;106:336–356.</p>
			</div>
			<p class="h1 ParaOverride-14">Eyelid Diseases Associated With Ocular Surface Disease</p>
			<div id="Chapt3_Top4">
			<p class="h2-h1">Rosacea</p>
			<p class="h5-text ParaOverride-1 body-text--no-indent-"><span class="h5-head">pathogenesis</span> Rosacea (sometimes called <span class="italic">acne rosacea</span>) is a chronic dermatological disease that can affect both the skin and the eyes. It has no proven cause, but bacteria associated with <span class="italic">Demodex</span> mites have been implicated. The condition may be related to the overexpression of cathelicidin. Cathelicidins, cationic peptides with antimicrobial activity, contribute to neutrophil recruitment, angiogenesis, and cytokine release, which may play a role in the inflammatory skin changes seen in patients with rosacea. Rosacea is associated with cutaneous sebaceous gland dysfunction of the face, neck, and shoulders. Although rosacea has generally been thought to be more common in fair-&#173;skinned individuals, it may simply be more difficult to diagnose in patients with dark skin. It is important to look for the sometimes subtle clinical findings by external examination in a brightly lit room. Although alcohol consumption can contribute to a worsening of this disorder because of its effect on vasomotor stability, most patients with rosacea do not have a history of excessive alcohol intake. In some patients, exacerbation can be triggered by emotional stress, ingestion of hot or spicy foods, or a hot or cold environment.</p>
			<p class="h5-text ParaOverride-15"><span class="h5-head">clinical presentation</span> Rosacea frequently involves the eyes. It affects individuals aged 30–60&#160;years most commonly and women slightly more often than men, although ocular rosacea can occur in young patients and is often underdiagnosed. Rosacea is characterized by excessive sebum secretion with frequently recalcitrant chronic blepharitis. Eyelid margin telangiectasia is very common, and the often-&#173;associated meibomian gland distortion, disruption, and dysfunction can lead to recurrent chalazia. The ocular condition can progress, leading to chronic conjunctivitis, severe stromal keratitis (<span class="xref-figure">Fig&#160;3-14</span>), marginal keratitis (<span class="xref-figure">Fig&#160;3-15A</span>), sterile ulceration, episcleritis, or iridocyclitis. If properly treated, these lesions can resolve with few sequelae. Repeated bouts of ocular surface inflammation can cause corneal neovascularization and scarring (Fig&#160;3-15B).</p>
			<p class="body-text--no--indent-">Facial lesions consist of telangiectasias, recurrent papules and pustules, and midfacial erythema (<span class="xref-figure">Fig&#160;3-16</span>). Rosacea is characterized by a malar rash with unpredictable flushing episodes. Rhinophyma, thickening of the skin and connective tissue of the nose, is a characteristic and obvious sign associated with this disorder, but such hypertrophic cutaneous changes occur relatively late in the disease process.</p>
			<p class="h5-text ParaOverride-16"><span class="h5-head">management</span> The ocular and systemic diseases are managed simultaneously, and oral tetracyclines are the mainstay of therapy. Tetracyclines have anti-&#173;inflammatory properties that include suppression of leukocyte migration, reduced production of nitric oxide and reactive oxygen species, inhibition of matrix metalloproteinases, and inhibition of phospholipase&#160;A2. In addition, tetracyclines may reduce irritative free fatty acids and diglycerides by suppressing bacterial lipases. Erythromycin or azithromycin may be used when tetracyclines are not appropriate. Oral azithromycin should not be used in patients prone to cardiac arrhythmia.</p>
			<p class="body-text">With time, oral therapy with doxycycline or minocycline can be tapered. In addition to oral therapy, topical therapy with metronidazole gel 0.75%, metronidazole cream 1%, or azelaic acid gel 15% applied to the affected facial areas can significantly reduce facial erythema. Azelaic acid 15%, the only gel approved by the FDA for the treatment of papulopustular rosacea, is thought to suppress rosacea through anti-&#173;inflammatory and antimicrobial mechanisms.</p>
			<p class="body-text">Ulcerative keratitis in rosacea can be associated with infection or due to a sterile inflammatory response. Once it is ascertained that ulceration is noninfectious, topical corticosteroids, used judiciously, can play a significant role in reducing sterile inflammation and enhancing epithelialization of the cornea. In advanced cases with scarring and neovascularization, conservative therapy is generally recommended. Penetrating keratoplasty is a high-risk procedure in the rosacea patient, and the prognosis may be poor, particularly if the ocular surface is severely compromised.</p>
			<p class="body-text">Intense pulsed-light therapy may help reduce eyelid erythema as well as symptoms related to meibomian gland dysfunction. See “Medical management of evaporative dry eye,” earlier in the chapter.</p>
			<p class="reference-first ParaOverride-16">National Rosacea Society website. Available at www.rosacea.org. Accessed February 3, 2017.</p>
			<p class="reference-last--no-space-">Schittek B, Paulmann M, Senyürek I, Steffen H. The role of antimicrobial peptides in human skin and in skin infectious diseases. <span class="italic">Infect Disord Drug Targets.</span> 2008;8(3):135–143.</p>
			<p class="h2">Seborrheic Blepharitis</p>
			<p class="h5-text ParaOverride-1"><span class="h5-head">clinical presentation</span> Seborrheic blepharitis may occur alone or in combination with staphylococcal blepharitis, MGD, or seborrheic dermatitis. Inflammation occurs primarily at the anterior eyelid margin; a variable amount of scaling or scurf (<span class="xref-figure">Fig&#160;3-17</span>), typically of an oily or greasy consistency, may be found on the eyelids, eyelashes, eyebrows, and scalp. Patients with seborrheic blepharitis often have increased meibomian gland secretions that appear turbid when expressed. Additional signs and symptoms include chronic eyelid redness, burning, and, occasionally, foreign-&#173;body sensation. In a small percentage of patients (approximately 15%), an associated keratitis or conjunctivitis develops. The keratitis is characterized by punctate epithelial erosions distributed over the inferior one-third of the cornea. Approximately one-third of patients with seborrheic blepharitis have evaporative dry eye. See <span class="xref-table">Table&#160;3-11</span> for additional information on seborrheic and other types of blepharitis.</p>
			<p class="h5-text"><span class="h5-head">management</span> Eyelid hygiene (discussed elsewhere in this chapter) is the primary treatment for seborrheic blepharitis as well as the associated MGD or staphylococcal blepharitis. Concurrent treatment of the scalp disease with selenium sulfide shampoos is recommended.</p>
			<p class="body-text">Demodicosis should be considered in patients who do not improve with traditional blepharitis treatments. Eyelash sleeves are typically seen (<span class="xref-figure">Fig&#160;3-18A</span>; also see Fig&#160;3-17). In a recent small case series, improvement in symptoms and signs was seen when weekly 50% tea tree oil eyelid scrubs and daily tea tree oil shampoo scrubs were used for a minimum of 6&#160;weeks in a group of patients who had not improved with eyelid hygiene and concurrent scalp treatment. Oral ivermectin has also been reported to be of benefit in some cases of recalcitrant <span class="italic">Demodex</span> blepharitis.</p>
			<p class="h2">Staphylococcal Blepharitis</p>
			<p class="h5-text ParaOverride-1"><span class="h5-head">pathogenesis</span> In general, the term <span class="italic">staphylococcal blepharitis</span> (caused usually by <span class="italic">Staphylococcus aureus</span> but occasionally by other species) refers to cases in which bacterial infection of the eyelids (and frequently the conjunctiva) is predominant. MGD and seborrheic blepharitis, in contrast, are primarily inflammatory. Clinical features that may help in the differential diagnosis of these conditions are summarized in Table&#160;3-11.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> Staphylococcal blepharitis is seen more commonly in younger individuals. Symptoms include burning, itching, foreign-&#173;body sensation, and crusting, particularly upon awakening. Symptoms of irritation and burning tend to peak in the morning and improve as the day progresses, presumably as the crusted material that accumulates on the eyelid margin overnight is liberated.</p>
			<p class="body-text">Typical clinical manifestations include hard, brittle fibrinous scales and hard, matted crusts surrounding individual cilia (collarettes) on the anterior eyelid margin (Fig&#160;3-18B). Small ulcers of the anterior eyelid margin may be seen when the hard crusts are removed (see Fig&#160;3-17). Injection and telangiectasis of the anterior and posterior eyelid margins, white lashes (poliosis), lash loss (madarosis), and trichiasis may be seen in varying degrees, depending on the severity and duration of the blepharitis.</p>
			<p class="body-text">Staphylococcal blepharoconjunctivitis may present as a chronic (&gt;4-week duration) unilateral or bilateral conjunctivitis. Clinical findings include a papillary reaction of the tarsal conjunctiva, particularly the inferior tarsal conjunctiva near the eyelid margin, as well as injection of the bulbar and tarsal conjunctivae. Conjunctival injection is mild and mucopurulent discharge scant. Concomitant ATD and/or lipid-&#173;induced tear film instability may also occur. If unilateral signs or symptoms persist, the clinician should consider obstruction of the nasolacrimal system and perform a dye disappearance test or perhaps irrigation of the nasolacrimal system.</p>
			<p class="body-text">Specific clinical signs in patients with chronic conjunctivitis may implicate certain bacterial species. <span class="italic">Staphylococcus aureus</span> is often associated with matted, honey-&#173;colored crusts and ulcers on the anterior eyelid margin, inferior punctate keratopathy, marginal corneal infiltrates, and, in rare cases, conjunctival or corneal phlyctenules. <span class="italic">Moraxella lacunata</span> may cause a chronic angular blepharoconjunctivitis, with crusting and ulceration of the skin in the lateral canthal angle and a papillary or follicular reaction on the tarsal conjunctiva, sometimes with adjacent keratitis. <span class="italic">Moraxella</span> angular blepharoconjunctivitis is frequently associated with concomitant <span class="italic">S aureus</span> blepharoconjunctivitis.</p>
			<p class="body-text">Several forms of keratitis may develop in association with staphylococcal blepharoconjunctivitis. Punctate epithelial keratopathy manifests as erosions that stain with fluorescein; these erosions are often distributed across the inferior cornea, coinciding with the contour of the eyelids across the corneal surface. A diffuse pattern may also be observed, and asymmetric or unilateral keratopathy is not uncommon. The degree of corneal involvement can be markedly disproportionate to the severity of the eyelid disease, a circumstance that can lead to diagnostic confusion. Marginal corneal infiltrates may be the most distinctive clinical finding, with creamy white elliptical opacities typically separated from the limbus by a relatively lucent zone. They most often occur near the point of intersection of the eyelid margin and the limbus, that is, at 10, 2, 4 and 8&#160;o’clock (<span class="xref-figure">Fig&#160;3-19</span>; also see Fig&#160;3-15A).</p>
			<p class="body-text">Phlyctenulosis is a local corneal and/or conjunctival inflammation that is believed to represent a cell-&#173;mediated, or delayed, hypersensitivity response induced by microbial antigens such as the cell wall components of staphylococcus. Phlyctenulosis is frequently associated with <span class="italic">S&#160;aureus</span> in developed countries and is classically associated with <span class="italic">Mycobacterium tuberculosis</span> infection affecting malnourished children in tuberculosis-&#173;endemic areas of the world.</p>
			<p class="body-text">Phlyctenules are hyperemic, focal nodules consisting of chronic inflammatory cells. They often present unilaterally at or near the limbus, on the bulbar conjunctiva or cornea, as small, round, elevated, gray or yellow nodules accompanied by a zone of engorged hyperemic vessels (<span class="xref-figure">Fig&#160;3-20A</span>). Phlyctenules typically become necrotic and ulcerate centrally; they then spontaneously involute over a period of 2–3&#160;weeks. Conjunctival phlyc&#173;tenules do not lead to scarring, but residual wedge-shaped fibrovascular corneal scars form along the limbus; when such scars are bilateral and inferior, they may suggest previous phlyctenulosis. Corneal involvement is recurrent, and centripetal migration of successive inflammatory lesions may eventually occur, affecting vision if untreated (Fig&#160;3-20B). Occasionally, such inflammation leads to corneal thinning and, in rare cases, perforation.</p>
			<p class="h5-text ParaOverride-17"><span class="h5-head">laboratory evaluation</span> Eyelid and conjunctival cultures can be performed in suspected cases of staphylococcal blepharoconjunctivitis when the initial diagnosis is in doubt, the treatment response is poor, or the infection is worsening. An antibiotic washout period of at least a week should be employed prior to culture. In chronic unilateral conjunctivitis refractory to therapy, conjunctival malignancy (eg, sebaceous cell carcinoma) and factitious illness should be ruled out.</p>
			<p class="body-text">The characteristic laboratory finding in staphylococcal blepharoconjunctivitis is a heavy, confluent growth of <span class="italic">S&#160;aureus.</span> Nevertheless, the finding of a light to moderate growth of bacteria and/or the isolation of staphylococcal species other than <span class="italic">S&#160;aureus</span> does not exclude the diagnosis, particularly if a predominant manifestation of the disease is punctate epithelial keratopathy, marginal infiltrates, or phlyctenulosis. Susceptibility testing may be useful in guiding treatment in cases that have been refractory to empiric antibiotic therapy.</p>
			<p class="h5-text"><span class="h5-head">management</span> Effective treatment addresses both the infection and the associated inflammation. Eyelid hygiene, with either commercially available eyelid scrub kits or warm water mixed with baby shampoo, may help reduce bacterial colonization and the accumulation of sebaceous secretions. With these treatments, patients should focus their attention on the base of the lashes, where colonization and seborrhea are the greatest. Aggressive scrubbing should be discouraged. Topical bacitracin, erythromycin, azithromycin, or tobramycin may be applied to the eyelid margin to reduce both the bacterial load and associated inflammation. As stated earlier, ATD and/or lipid-&#173;induced tear film instability may occur concomitantly; these should be treated to improve patient comfort. Because many strains of bacteria have developed resistance to sulfa drugs, these antibiotics are less efficacious in the treatment of staphylococcal blepharitis.</p>
			<p class="body-text">In selected cases, anti-&#173;inflammatory therapy consists of limited use of mild doses of topical corticosteroids. Phlyctenulosis and staphylococcal marginal keratitis readily respond to judicious use of topical steroids used in concert with antibiotic therapy and eyelid hygiene. If epithelial defects are noted over the infiltrates, diagnostic cultures should be considered before corticosteroid treatment is begun. Long-term or indiscriminate use of corticosteroids should always be avoided.</p>
			<p class="body-text">Patients with routine staphylococcal blepharitis or blepharoconjunctivitis obtain more rapid symptomatic relief with adjunct topical corticosteroids; however, punctate epithelial keratopathy related to drug toxicity is unlikely to respond. The long-term use of topical corticosteroids should be weighed against the risk of adverse effects and, less likely, further proliferation of the pathogen.</p>
			<p class="h2">Hordeola and Chalazia</p>
			<p class="h5-text ParaOverride-1"><span class="h5-head">clinical presentation</span> Hordeola present as painful, tender, red nodular masses near the eyelid margin (<span class="xref-figure">Fig&#160;3-21</span>). Those occurring on the anterior eyelid in the glands of Zeis or lash follicles are called <span class="italic">external hordeola,</span> or <span class="italic">styes.</span> Hordeola occurring on the posterior eyelid from meibomian gland inspissation are termed <span class="italic">internal hordeola.</span> Both types are associated with a localized purulent abscess, usually caused by <span class="italic">S&#160;aureus,</span> and may rupture, producing a purulent drainage. Hordeola are generally self-&#173;limited, improving spontaneously over the course of 1–2&#160;weeks.</p>
			<p class="body-text">Internal hordeola occasionally evolve into chalazia, which are chronic lipogranulomatous nodules involving either the meibomian glands or the glands of Zeis. The lesion disappears in weeks to months, when the sebaceous contents drain either externally through the eyelid skin or internally through the tarsus or when the extruded lipid is phagocytosed and the granuloma dissipates. A small amount of scar tissue may remain. Occasionally, patients with a chalazion experience blurred vision secondary to astigmatism induced by its pressure on the globe. Basal cell, squamous cell, and sebaceous cell carcinoma can masquerade as chalazia or chronic blepharitis. The histologic examination of persistent, recurrent, or atypical chalazia is therefore important. Lash loss occurring over a chronic lesion is suggestive of malignancy.</p>
			<p class="h5-text"><span class="h5-head">management</span> Cultures are not indicated for isolated, uncomplicated cases of hordeolum or chalazion. Warm compresses can facilitate drainage. Topically applied antibiotics are generally not effective and, therefore, are not indicated unless an accompanying infectious blepharoconjunctivitis is present. Systemic antibiotics are generally indicated only in cases of secondary eyelid cellulitis. If the patient has a prominent and chronic accompanying meibomitis, oral doxycycline may be necessary.</p>
			<p class="body-text">If an internal hordeolum evolves into a chalazion that fails to respond to warm compresses and eyelid hygiene, intralesional injection of a corticosteroid (eg, 0.1–0.2&#160;mL of triamcinolone 40&#160;mg/mL), incision and curettage, or both may be necessary. In general, intralesional corticosteroid injection works best with small chalazia, chalazia on the eyelid margin, and multiple chalazia. Intralesional corticosteroid injection in patients with dark skin may lead to depigmentation of the overlying eyelid skin and thus should be used with caution. Oral doxycycline can be helpful for a patient with recurrent chalazia.</p>
			<p class="body-text">Large chalazia are best treated with surgical drainage and curettage. Internal chalazia require vertical incisions through the tarsal conjunctiva along the meibomian gland to facilitate drainage and avoid horizontal scarring of the tarsal plates. Surgical drainage usually requires perilesional anesthesia. A biopsy should be performed for recurrent chalazia to rule out meibomian gland carcinoma.</p>
			<p class="body-text">See also BCSC Section&#160;7, <span class="italic">Orbit, Eyelids, and Lacrimal System,</span> for further discussion of chalazion.</p>
		</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer003">
				<div id="_idContainer001" class="Basic-Text-Frame">
					<table id="table001" class="No-Table-Style TableOverride-1">
						<colgroup>
							<col class="_idGenTableRowColumn-1" />
							<col class="_idGenTableRowColumn-2" />
							<col class="_idGenTableRowColumn-3" />
							<col class="_idGenTableRowColumn-2" />
							<col class="_idGenTableRowColumn-4" />
						</colgroup>
						<tbody>
							<tr class="No-Table-Style _idGenTableRowColumn-5">
								<td class="No-Table-Style CellOverride-1 _idGenCellOverride-1" colspan="5">
									<p class="table-title"><span class="table-number">Table 3-1</span> Common Clinical Findings of the External Eye and Cornea</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-6">
								<td class="No-Table-Style CellOverride-2">
									<p class="table-column-head">Tissue</p>
								</td>
								<td class="No-Table-Style CellOverride-2" />
								<td class="No-Table-Style CellOverride-2">
									<p class="table-column-head">Finding</p>
								</td>
								<td class="No-Table-Style CellOverride-2" />
								<td class="No-Table-Style CellOverride-2">
									<p class="table-column-head">Description</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-7">
								<td class="No-Table-Style CellOverride-3">
									<p class="table-body"><span class="CharOverride-2">Eyelid</span></p>
								</td>
								<td class="No-Table-Style CellOverride-3" />
								<td class="No-Table-Style CellOverride-3">
									<p class="table-body">Macule</p>
								</td>
								<td class="No-Table-Style CellOverride-3" />
								<td class="No-Table-Style CellOverride-3">
									<p class="table-body">Spot of skin color change</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-8">
								<td class="No-Table-Style CellOverride-4" />
								<td class="No-Table-Style CellOverride-4" />
								<td class="No-Table-Style CellOverride-4">
									<p class="table-body">Papule</p>
								</td>
								<td class="No-Table-Style CellOverride-4" />
								<td class="No-Table-Style CellOverride-4">
									<p class="table-body">Small, solid elevation of the skin</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-8">
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5">
									<p class="table-body">Vesicle</p>
								</td>
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5">
									<p class="table-body">Blister filled with serous fluid</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-8">
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5">
									<p class="table-body">Bulla</p>
								</td>
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5">
									<p class="table-body">Large blister</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-8">
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5">
									<p class="table-body">Pustule</p>
								</td>
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5">
									<p class="table-body">Pus-filled blister</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-8">
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5">
									<p class="table-body">Keratosis</p>
								</td>
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5">
									<p class="table-body">Scaling from accumulated keratinized cells</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-8">
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5">
									<p class="table-body">Eczema</p>
								</td>
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5">
									<p class="table-body">Scaly crust on a red base</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-8">
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5">
									<p class="table-body">Erosion</p>
								</td>
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5">
									<p class="table-body">Excoriated epidermal defect</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-8">
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5">
									<p class="table-body">Ulcer</p>
								</td>
								<td class="No-Table-Style CellOverride-5" />
								<td class="No-Table-Style CellOverride-5">
									<p class="table-body">Epidermal erosion with deeper tissue loss</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-9">
								<td class="No-Table-Style CellOverride-6">
									<p class="table-body"><span class="CharOverride-2">Conjunctiva</span></p>
								</td>
								<td class="No-Table-Style CellOverride-6" />
								<td class="No-Table-Style CellOverride-6">
									<p class="table-body">Hyperemia</p>
								</td>
								<td class="No-Table-Style CellOverride-6" />
								<td class="No-Table-Style CellOverride-6">
									<p class="table-body">Focal or diffuse dilation of the subepithelial plexus of conjunctival blood vessels, usually with increased blood flow; other changes include fusiform vascular dilations, saccular aneurysms, petechiae, and intra-conjunctival hemorrhage</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-10">
								<td class="No-Table-Style CellOverride-7" />
								<td class="No-Table-Style CellOverride-7" />
								<td class="No-Table-Style CellOverride-7">
									<p class="table-body">Chalasis</p>
								</td>
								<td class="No-Table-Style CellOverride-7" />
								<td class="No-Table-Style CellOverride-7">
									<p class="table-body">Laxity of conjunctiva; tissue may roll up onto the eyelid margin or cover the lacrimal punctum</p>
								</td>
							</tr>
						</tbody>
					</table>
				</div>
				<div id="_idContainer002" class="Basic-Text-Frame">
					<p class="table-cont-line">(Continued)</p>
				</div>
			</div>
		</div>
		<div id="_idContainer004" class="Basic-Text-Frame">
			<table id="table002" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-11" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-3" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-12" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style CellOverride-8" colspan="5">
							<p class="table-title"><span class="table-number">Table 3-1</span> <span class="CharOverride-3">(continued)</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style CellOverride-9">
							<p class="table-column-head">Tissue</p>
						</td>
						<td class="No-Table-Style CellOverride-9" />
						<td class="No-Table-Style CellOverride-9">
							<p class="table-column-head">Finding</p>
						</td>
						<td class="No-Table-Style CellOverride-9" />
						<td class="No-Table-Style CellOverride-9">
							<p class="table-column-head">Description</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-13">
						<td class="No-Table-Style CellOverride-10" />
						<td class="No-Table-Style CellOverride-10" />
						<td class="No-Table-Style CellOverride-10">
							<p class="table-body">Chemosis</p>
						</td>
						<td class="No-Table-Style CellOverride-10" />
						<td class="No-Table-Style CellOverride-10">
							<p class="table-body">Conjunctival edema caused by a transudate leaking through fenestrated conjunctival capillaries as a result of altered vascular integrity (eg, inflammation and vasomotor changes) or hemodynamic changes (eg, impaired venous drainage or intravascular hyposmolarity)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Epiphora</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Excess tears from increased lacrimation or impaired lacrimal outflow</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-6" />
						<td class="No-Table-Style CellOverride-6" />
						<td class="No-Table-Style CellOverride-6">
							<p class="table-body">Mucus excess</p>
						</td>
						<td class="No-Table-Style CellOverride-6" />
						<td class="No-Table-Style CellOverride-6">
							<p class="table-body">Increased amount of mucin relative to aqueous component of tears</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-11" />
						<td class="No-Table-Style CellOverride-11" />
						<td class="No-Table-Style CellOverride-11">
							<p class="table-body">Discharge</p>
						</td>
						<td class="No-Table-Style CellOverride-11" />
						<td class="No-Table-Style CellOverride-11">
							<p class="table-body">Exudate on the conjunctival surface, varying from proteinaceous (serous) to cellular (purulent)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-15">
						<td class="No-Table-Style CellOverride-11" />
						<td class="No-Table-Style CellOverride-11" />
						<td class="No-Table-Style CellOverride-11">
							<p class="table-body">Papillae</p>
						</td>
						<td class="No-Table-Style CellOverride-11" />
						<td class="No-Table-Style CellOverride-11">
							<p class="table-body">Dilated, telangiectatic conjunctival blood vessels, varying from dotlike changes to enlarged tufts, surrounded by edema and a mixed inflammatory cell infiltrate</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-11" />
						<td class="No-Table-Style CellOverride-11" />
						<td class="No-Table-Style CellOverride-11">
							<p class="table-body">Follicle</p>
						</td>
						<td class="No-Table-Style CellOverride-11" />
						<td class="No-Table-Style CellOverride-11">
							<p class="table-body">Focal lymphoid nodule with accessory vascularization</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-12" />
						<td class="No-Table-Style CellOverride-12" />
						<td class="No-Table-Style CellOverride-12">
							<p class="table-body">Pseudomembrane</p>
						</td>
						<td class="No-Table-Style CellOverride-12" />
						<td class="No-Table-Style CellOverride-12">
							<p class="table-body">Inflammatory coagulum on the conjunctival surface that does not bleed during removal</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Membrane</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Inflammatory coagulum suffusing the conjunctival epithelium that bleeds when stripped</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Granuloma</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Nodule consisting of chronic inflammatory cells with fibrovascular proliferation</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Phlyctenule</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Nodule consisting of chronic inflammatory cells, often at or near the limbus</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Punctate epithelial erosion</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Loss of individual epithelial cells in a stippled pattern</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Epithelial defect</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Focal area of epithelial loss</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body"><span class="CharOverride-2">Sclera</span></p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Episcleritis</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Focal or diffuse dilation of radial superficial episcleral vessels</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Nonnecrotizing<br />scleritis</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Dilated deep episcleral vessels with scleral edema</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Necrotizing scleritis</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Area of avascular sclera</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body"><span class="CharOverride-2">Co</span><span class="CharOverride-2">r</span><span class="CharOverride-2">nea</span></p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Punctate epithelial erosion</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Fine, slightly depressed stippling caused by altered or desquamated superficial epithelium</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-15">
						<td class="No-Table-Style CellOverride-6" />
						<td class="No-Table-Style CellOverride-6" />
						<td class="No-Table-Style CellOverride-6">
							<p class="table-body">Punctate epithelial keratitis</p>
						</td>
						<td class="No-Table-Style CellOverride-6" />
						<td class="No-Table-Style CellOverride-6">
							<p class="table-body">Swollen, slightly raised epithelial cells that can be finely scattered, coarsely grouped, or arranged in an arborescent pattern</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-13" />
						<td class="No-Table-Style CellOverride-13" />
						<td class="No-Table-Style CellOverride-13">
							<p class="table-body">Epithelial edema</p>
						</td>
						<td class="No-Table-Style CellOverride-13" />
						<td class="No-Table-Style CellOverride-13">
							<p class="table-body">Swollen epithelial cells (intraepithelial edema) or intercellular vacuoles (microcystic edema)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-14" />
						<td class="No-Table-Style CellOverride-14" />
						<td class="No-Table-Style CellOverride-14">
							<p class="table-body">Bulla</p>
						</td>
						<td class="No-Table-Style CellOverride-14" />
						<td class="No-Table-Style CellOverride-14">
							<p class="table-body">Fluid pocket within or under the epithelium</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Epithelial defect</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Focal area of epithelial loss, caused by trauma (abrasion) or other condition</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Dendrite</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Branching linear epithelial ridge with swollen cells, terminal bulbs, and possible central ulceration</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Ulcer</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Epithelial defect, stromal loss, stromal inflammation, or any combination of these changes</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-15">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Filament</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Strand (filament) or clump (mucous plaque) of mucus and degenerating epithelial cells attached to an altered ocular surface</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Subepithelial<br />infiltrate</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Coin-shaped inflammatory opacity in the anterior portion of Bowman layer</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Suppurative<br />stromal keratitis</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Focal yellow-white infiltrate of neutrophils</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-16">
						<td class="No-Table-Style CellOverride-15" />
						<td class="No-Table-Style CellOverride-15" />
						<td class="No-Table-Style CellOverride-15">
							<p class="table-body">Nonsuppurative<br />stromal keratitis</p>
						</td>
						<td class="No-Table-Style CellOverride-15" />
						<td class="No-Table-Style CellOverride-15">
							<p class="table-body">Focal gray-white infiltrate of lymphocytes and other mononuclear cells; also called <span class="CharOverride-3">interstitial keratitis,</span> especially when accompanied by stromal neovascularization</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer005" class="Basic-Text-Frame">
			<table id="table003" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-17" />
					<col class="_idGenTableRowColumn-18" />
					<col class="_idGenTableRowColumn-19" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style CellOverride-1 _idGenCellOverride-1" colspan="3">
							<p class="table-title"><span class="table-number">Table 3-2</span> Conjunctival Signs</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style CellOverride-2">
							<p class="table-column-head">Finding</p>
						</td>
						<td class="No-Table-Style CellOverride-2" />
						<td class="No-Table-Style CellOverride-2">
							<p class="table-column-head">Examples of Ocular or Systemic Conditions</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-7">
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Papillary conjunctivitis</p>
						</td>
						<td class="No-Table-Style CellOverride-3" />
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Allergic conjunctivitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-4" />
						<td class="No-Table-Style CellOverride-4" />
						<td class="No-Table-Style CellOverride-4">
							<p class="table-body">Bacterial conjunctivitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Follicular conjunctivitis</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Adenovirus conjunctivitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Herpes simplex virus conjunctivitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Molluscum contagiosum blepharoconjunctivitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Chlamydial conjunctivitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Drug-induced (eg, brimonidine) conjunctivitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Conjunctival pseudomembrane or membrane</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Severe viral or bacterial conjunctivitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Stevens-Johnson syndrome</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Chemical burn</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Conjunctival granuloma</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Cat-scratch disease</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Sarcoidosis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Foreign-body reaction</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Conjunctival erosion or ulceration</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Stevens-Johnson syndrome</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Mucous membrane pemphigoid</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Graft-vs-host disease</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Factitious conjunctivitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-16" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-16" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-16">
							<p class="table-body">Mechanical or chemical trauma</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Conjunctival cicatrization</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Stevens-Johnson syndrome</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Mucous membrane pemphigoid</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-17" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-17" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-17">
							<p class="table-body">Chemical injury</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer008">
				<div id="_idContainer006" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-2681.png" alt="" />
				</div>
				<div id="_idContainer007" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 3-1</span> Cross-&#173;sectional diagram of a conjunctival papilla with a central vascular tuft sur-<br />rounded by acute and chronic leukocytes.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer009" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-2796.png" alt="" />
			</div>
		</div>
		<div id="_idContainer010" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 3-2</span> Papillary conjunctivitis. <span class="figure-caption-bold">A,</span>&#160;Mild papillae. <span class="figure-caption-bold">B,</span>&#160;Moderate papillae. <span class="figure-caption-bold">C,</span>&#160;Marked (giant) papillae.</p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer013">
				<div id="_idContainer011" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-2682.png" alt="" />
				</div>
				<div id="_idContainer012" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 3-3</span> Cross-&#173;sectional diagram of a conjunctival follicle with mononuclear cells obscuring conjunctival blood vessels.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer016">
				<div id="_idContainer014" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-3542.png" alt="" />
				</div>
				<div id="_idContainer015" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 3-5</span> Follicular conjunctivitis. <span class="figure-caption-bold">A,</span>&#160;Inflammation of the right eye from glaucoma medication. <span class="figure-caption-bold">B,</span>&#160;Right eye showing follicular conjunctivitis in the inferior fornix. <span class="figure-source-note">(Courtesy of John&#160;E. Sutphin, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer019">
				<div id="_idContainer017" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-2798.jpg" alt="" />
				</div>
				<div id="_idContainer018" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 3-4</span> Benign lymphoid folliculosis. <span class="figure-source-note">(Cou</span><span class="figure-source-note">r</span><span class="figure-source-note">-<br />tesy of Kirk&#160;R. Wilhelmus, MD.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer020" class="Basic-Text-Frame">
			<table id="table004" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-20" />
					<col class="_idGenTableRowColumn-21" />
					<col class="_idGenTableRowColumn-22" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style CellOverride-1 _idGenCellOverride-1" colspan="3">
							<p class="table-title"><span class="table-number">Table 3-3</span> Corneal Signs</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style CellOverride-2">
							<p class="table-column-head">Finding</p>
						</td>
						<td class="No-Table-Style CellOverride-2" />
						<td class="No-Table-Style CellOverride-2">
							<p class="table-column-head">Examples of Ocular Conditions</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-7">
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Punctate epithelial erosions</p>
						</td>
						<td class="No-Table-Style CellOverride-3" />
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Dry eye</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-4" />
						<td class="No-Table-Style CellOverride-4" />
						<td class="No-Table-Style CellOverride-4">
							<p class="table-body">Toxic reaction</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Atopic keratoconjunctivitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Punctate epithelial keratitis</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Adenovirus keratoconjunctivitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Herpes simplex virus epithelial keratitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Herpes zoster virus epithelial keratitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Thygeson superficial punctate keratitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Stromal keratitis, suppurative</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Bacterial keratitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Fungal keratitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" rowspan="2">
							<p class="table-body">Stromal keratitis, nonsuppurative</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Herpes simplex virus stromal keratitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Varicella-zoster virus stromal keratitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Syphilitic interstitial keratitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Peripheral keratitis</p>
						</td>
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Blepharitis-associated marginal infiltrates</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5" />
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">Peripheral ulcerative keratitis caused by connective tissue diseases</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style CellOverride-15" />
						<td class="No-Table-Style CellOverride-15" />
						<td class="No-Table-Style CellOverride-15">
							<p class="table-body">Mooren ulcer</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer023">
				<div id="_idContainer021" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/KIN00919.png" alt="" />
				</div>
				<div id="_idContainer022" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 3-6</span> Punctate lesions of the corneal epithelium. <span class="figure-caption-bold">A,</span>&#160;Punctate epithelial erosions. <span class="figure-caption-bold">B,</span>&#160;Punctate epithelial keratitis. <span class="figure-caption-bold">C,</span>&#160;Slit-lamp photograph from a patient with epithelial keratitis due to herpes zoster. <span class="figure-source-note">(Part&#160;C courtesy of Robert&#160;S. Feder, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer026">
				<div id="_idContainer024" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/KIN00920.png" alt="" />
				</div>
				<div id="_idContainer025" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 3-7</span> Inflammation of the corneal stroma. <span class="figure-caption-bold">A,</span>&#160;Suppurative keratitis. <span class="figure-caption-bold">B,</span>&#160;Nonsuppurative, nonnecrotizing (disciform) stromal keratitis. <span class="figure-caption-bold">C,</span>&#160;Immune ring. <span class="figure-caption-bold">D,</span>&#160;Peripheral ulcerative keratitis. An ovoid area of thinning <span class="figure-caption-italic">(arrow)</span> can be seen in the inferonasal quadrant. <span class="figure-source-note">(Parts&#160;C and D courtesy of Robert&#160;S. Feder, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer029">
				<div id="_idContainer027" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-2793.png" alt="" />
				</div>
				<div id="_idContainer028" class="Basic-Text-Frame">
					<p class="figure-caption ParaOverride-18"><span class="figure-number">Figure 3-8</span> Corneal pannus. <span class="figure-source-note">(Courtesy of Kirk&#160;R. Wilhelmus, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer032">
				<div id="_idContainer030" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-6744.png" alt="" />
				</div>
				<div id="_idContainer031" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 3-9</span> The mechanisms of dry eye. <span class="figure-source-note">(Modified with permission from The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007).</span> <span class="figure-source-emphasis">Ocul Surf.</span> <span class="figure-source-note">2007;5(2):75–92.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer035">
				<div id="_idContainer033" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-6745.png" alt="" />
				</div>
				<div id="_idContainer034" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 3-10</span> Diagnostic classification scheme for dry eye disorders. <span class="figure-source-note">(Courtesy of Minas&#160;T. Coroneo, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer038">
				<div id="_idContainer036" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-6750.png" alt="" />
				</div>
				<div id="_idContainer037" class="Basic-Text-Frame">
					<p class="figure-caption ParaOverride-18"><span class="figure-number">Figure 3-11</span> Filamentary keratopathy in a vascularized cornea. <span class="figure-source-note">(Courtesy of Minas&#160;T. Coroneo, MD.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer039" class="Basic-Text-Frame">
			<table id="table005" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-23" />
					<col class="_idGenTableRowColumn-24" />
					<col class="_idGenTableRowColumn-25" />
					<col class="_idGenTableRowColumn-24" />
					<col class="_idGenTableRowColumn-26" />
					<col class="_idGenTableRowColumn-24" />
					<col class="_idGenTableRowColumn-27" />
					<col class="_idGenTableRowColumn-24" />
					<col class="_idGenTableRowColumn-27" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="9">
							<p class="table-title"><span class="table-number">Table 3-4</span> Dry Eye Severity Grading Scheme</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-28">
						<td class="Basic-Table CellOverride-18" />
						<td class="Basic-Table CellOverride-18" />
						<td class="Basic-Table CellOverride-18" colspan="7">
							<p class="table-subhead">Dry Eye Severity Level</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-29">
						<td class="Basic-Table CellOverride-19">
							<p class="table-column-head">Signs and Symptoms </p>
						</td>
						<td class="Basic-Table CellOverride-19" />
						<td class="Basic-Table CellOverride-19">
							<p class="table-column-head ParaOverride-18">1</p>
						</td>
						<td class="Basic-Table CellOverride-19" />
						<td class="Basic-Table CellOverride-19">
							<p class="table-column-head ParaOverride-18">2</p>
						</td>
						<td class="Basic-Table CellOverride-19" />
						<td class="Basic-Table CellOverride-19">
							<p class="table-column-head ParaOverride-18">3</p>
						</td>
						<td class="Basic-Table CellOverride-19" />
						<td class="Basic-Table CellOverride-19">
							<p class="table-column-head ParaOverride-18">4*</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-13">
						<td class="Basic-Table CellOverride-18">
							<p class="table-body">Discomfort, severity and frequency</p>
						</td>
						<td class="Basic-Table CellOverride-18" />
						<td class="Basic-Table CellOverride-18">
							<p class="table-body">Mild and/or episodic; occurs under environmental stress</p>
						</td>
						<td class="Basic-Table CellOverride-18" />
						<td class="Basic-Table CellOverride-18">
							<p class="table-body">Moderate episodic or chronic, stress or no stress</p>
						</td>
						<td class="Basic-Table CellOverride-18" />
						<td class="Basic-Table CellOverride-18">
							<p class="table-body">Severe frequent or constant without stress</p>
						</td>
						<td class="Basic-Table CellOverride-18" />
						<td class="Basic-Table CellOverride-18">
							<p class="table-body">Severe and/or disabling and constant</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-30">
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Visual symptoms</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">None or episodic mild fatigue</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Annoying and/or activity-limiting episodic</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Annoying, chronic and/or constant, limiting activity</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Constant and/or possibly disabling</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Conjunctival injection</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">None to mild</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">None to mild</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">+/–</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">+/++</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Conjunctival staining</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">None to mild</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Variable</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Moderate to marked</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Marked</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Corneal staining (severity/location)</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">None to mild</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Variable</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Marked central</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Severe punctate erosions</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-31">
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Corneal/tear signs</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">None to mild</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Mild debris, <span class="math">↓</span>&#160;tear meniscus</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Filamentary keratitis, mucus clumping, <span class="math">↑</span>&#160;tear debris</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Filamentary keratitis, mucus clumping, <span class="math">↑</span>&#160;tear debris, ulceration</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Eyelid/meibomian glands</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">MGD variably present</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">MGD variably present</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">MGD frequently present</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Trichiasis, keratinization, symblepharon</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">TBUT (seconds)</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Variable</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">≤10</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">≤5</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Immediate</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-32">
						<td class="Basic-Table CellOverride-21">
							<p class="table-body">Schirmer score (mm wetting after 5 min)</p>
						</td>
						<td class="Basic-Table CellOverride-21" />
						<td class="Basic-Table CellOverride-21">
							<p class="table-body">Variable</p>
						</td>
						<td class="Basic-Table CellOverride-21" />
						<td class="Basic-Table CellOverride-21">
							<p class="table-body">≤10</p>
						</td>
						<td class="Basic-Table CellOverride-21" />
						<td class="Basic-Table CellOverride-21">
							<p class="table-body">≤5</p>
						</td>
						<td class="Basic-Table CellOverride-21" />
						<td class="Basic-Table CellOverride-21">
							<p class="table-body">≤2</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-33">
						<td class="Basic-Table CellOverride-22" colspan="9">
							<p class="table-footnote ParaOverride-19">MGD = meibomian gland dysfunction; TBUT = fluorescein tear break-up time; <span class="CharOverride-4">↓</span> = reduced; <span class="CharOverride-4">↑</span> = increased.</p>
							<p class="table-footnote"><span class="table-superscript-note-ast-">*</span>&#9;Must have signs AND symptoms.</p>
							<p class="table-source-note ParaOverride-13">Modified with permission from The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). <span class="table-source-emphasis">Ocul Surf.</span> 2007;5(2):75–92. Permission conveyed through Copyright Clearance Center, Inc.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer040" class="Basic-Text-Frame">
			<table id="table006" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-34" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style CellOverride-23">
							<p class="table-title"><span class="table-number">Table 3-5</span> Criteria for the Classification of Sjögren Syndrome</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-7">
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body"><span class="CharOverride-2">1. Ocular symptoms</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-4">
							<p class="table-body">  <span class="CharOverride-2">Definition:</span> A positive response to at least 1 of the following 3 questions:</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  a. Have you had daily, persistent, troublesome dry eyes for more than 3 months?</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  b. Do you have a recurrent sensation of sand or gravel in the eyes?</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  c. Do you use tear substitutes more than 3 times a day?</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body"><span class="CharOverride-2">2. Oral symptoms</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  <span class="CharOverride-2">Definition:</span> A positive response to at least 1 of the following 3 questions:</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  a. Have you had a daily feeling of dry mouth for more than 3 months?</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  b. Have you had recurrent or persistently swollen salivary glands as an adult?</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  c. Do you frequently drink liquids to aid in swallowing dry foods?</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body"><span class="CharOverride-2">3. Ocular signs</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-35">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  <span class="CharOverride-2">Definition: </span>Objective evidence of ocular involvement, determined on the basis of a positive result on at least 1 of the following 2 tests:</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  a. Schirmer I test (&lt;5.5 mm after 5 minutes)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  b. Rose bengal score (&gt;4 van Bijsterveld score)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body"><span class="CharOverride-2">4. Histopathologic features</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-35">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  <span class="CharOverride-2">Definition:</span> Focus score &gt;1 on minor salivary gland biopsy (<span class="CharOverride-3">focus</span> defined as a conglomeration of at least 50 mononuclear cells; <span class="CharOverride-3">focus score</span> defined as the number of foci in 4 mm<span class="CharOverride-5">2</span> of glandular tissue)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body"><span class="CharOverride-2">5. Salivary gland involvement</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-35">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  <span class="CharOverride-2">Definition:</span> Objective evidence of salivary gland involvement, determined on the basis of a positive result on at least 1 of the following 3 tests:</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  a. Salivary scintigraphy: delayed uptake and/or secretion</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  b. Parotid sialography: diffuse sialectasis without obstruction</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  c. Unstimulated salivary flow (&lt;1.5 mL in 15 minutes)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body"><span class="CharOverride-2">6. Autoantibodies</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  <span class="CharOverride-2">Definition:</span> Presence of at least 1 of the following serum autoantibodies:</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  a. Antibodies to Ro/SS-A</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body">  b. Antibodies to La/SS-B antigens</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-36">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body"><span class="CharOverride-2">Exclusion criteria:</span> Preexisting lymphoma, acquired immunodeficiency syndrome, sarcoidosis,</p>
							<p class="table-body">or chronic graft-vs-host disease, prior head and neck irradiation, hepatitis C, use of</p>
							<p class="table-body">anticholinergic medications</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-35">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body"><span class="CharOverride-2">Primary Sjögren syndrome:</span> Presence of 4 out of 6 items or presence of 3 of 4 objective criteria</p>
							<p class="table-body">(items 3–6)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-10">
						<td class="No-Table-Style CellOverride-24">
							<p class="table-body"><span class="CharOverride-2">Secondary Sjögren syndrome:</span> A combination of a positive response to item 1 or 2 plus a positive</p>
							<p class="table-body">response to at least 2 items from among 3, 4, and 5</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-37">
						<td class="No-Table-Style _8-BCSC-table-note">
							<p class="table-source-note">Modified with permission from Vitali C, Bombardieri S, Jonnson R, et al; European Study Group on Classification Criteria for Sjögren’s Syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. <span class="table-source-emphasis">Ann Rheum Dis.</span> 2002;61(6):557.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer041" class="Basic-Text-Frame">
			<table id="table007" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-34" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style CellOverride-23">
							<p class="table-title"><span class="table-number">Table 3-6</span> Systemic Diseases and Other Conditions Associated With Dry Eye</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-7">
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body"><span class="CharOverride-2">Autoimmune disorders</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-4">
							<p class="table-indent-1">Primary Sjögren syndrome</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Secondary Sjögren syndrome associated with</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-2">Rheumatoid arthritis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-2">Systemic lupus erythematosus</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-2">Progressive systemic sclerosis (scleroderma)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-2">Polymyositis and dermatomyositis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-2">Primary biliary cirrhosis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Graft-vs-host disease</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Immune reactions after radiation to head and neck</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body"><span class="CharOverride-2">Infiltrative processes</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Lymphoma</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Amyloidosis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Hemochromatosis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Sarcoidosis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body"><span class="CharOverride-2">Infectious processes</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">HIV-diffuse infiltrative lymphadenopathy syndrome</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Trachoma</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body"><span class="CharOverride-2">Neuropathic dysfunction</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Multiple sclerosis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Cranial neuropathies (Bell palsy, vasculitis)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Parkinson disease</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Alzheimer disease</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body"><span class="CharOverride-2">Endocrine dysfunction</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Androgen deficiency</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-body"><span class="CharOverride-2">Miscellaneous</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Familial dysautonomia (Riley-Day syndrome)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Congenital alacrima</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Anhidrotic ectodermal dysplasia</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style CellOverride-5">
							<p class="table-indent-1">Adie syndrome</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-10">
						<td class="No-Table-Style CellOverride-15">
							<p class="table-indent-1">Shy-Drager syndrome (idiopathic autonomic dysfunction with orthostatic hypotension and multiple system atrophy)</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer044">
				<div id="_idContainer042" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-2837.png" alt="" />
				</div>
				<div id="_idContainer043" class="Basic-Text-Frame">
					<p class="figure-caption ParaOverride-18"><span class="figure-number">Figure 3-12</span> Meibomian gland dysfunction.</p>
				</div>
			</div>
		</div>
		<div id="_idContainer045" class="Basic-Text-Frame">
			<table id="table008" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
					<col class="_idGenTableRowColumn-38" />
					<col class="_idGenTableRowColumn-39" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="3">
							<p class="table-title"><span class="table-number">Table 3-7</span> Therapeutic Options for Aqueous Tear Deficiency</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-25">
							<p class="table-column-head">Severity of ATD</p>
						</td>
						<td class="Basic-Table CellOverride-25" />
						<td class="Basic-Table CellOverride-25">
							<p class="table-column-head">Therapeutic Options</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-26">
							<p class="table-body">Mild</p>
						</td>
						<td class="Basic-Table CellOverride-26" />
						<td class="Basic-Table CellOverride-26">
							<p class="table-body">Tear substitutes with preservatives up to 4<span class="math">×</span> daily</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-body">Lubricating ointment at bedtime</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Hot compresses and eyelid massage</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Moderate</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Tear substitutes without preservatives 4<span class="math">×</span> daily to hourly</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Lubricating ointment at bedtime</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Topical anti-inflammatory treatment (cyclosporine A 0.05% 2<span class="math">×</span> daily)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Omega-3 supplement</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Reversible occlusion (plugs), lower puncta</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Systemic immunosuppression if ATD is associated with inflammatory connective tissue disease</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Severe</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">All of the above, plus one or more of the following:</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Punctal occlusion (upper and lower puncta); consider permanent occlusion</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Autologous serum drops (20%) 4–6<span class="math">×</span> daily</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Topical corticosteroids (nonpreserved if available) on a short-term basis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Humidifier</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Moisture-retaining eyewear</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Tarsorrhaphy (lateral and/or medial)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Bandage lenses (rarely)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-body">Scleral contact lens</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-21" />
						<td class="Basic-Table CellOverride-21" />
						<td class="Basic-Table CellOverride-21">
							<p class="table-body">Systemic cholinergic agonist (eg, pilocarpine)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-40">
						<td class="Basic-Table CellOverride-22" colspan="3">
							<p class="table-footnote">ATD = aqueous tear deficiency.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer046" class="Basic-Text-Frame">
			<table id="table009" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-41" />
					<col class="_idGenTableRowColumn-42" />
					<col class="_idGenTableRowColumn-41" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-10">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="3">
							<p class="table-title"><span class="table-number">Table 3-8</span> Medications With Anticholinergic Side Effects That Decrease Tear Production</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-26" />
						<td class="Basic-Table CellOverride-26">
							<p class="table-body"><span class="CharOverride-2">Antihypertensives</span></p>
						</td>
						<td class="Basic-Table CellOverride-26" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-27" />
						<td class="Basic-Table CellOverride-27">
							<p class="table-indent-1">Clonidine</p>
						</td>
						<td class="Basic-Table CellOverride-27" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Diuretics, sometimes in combination with other antihypertensive drugs</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Guanethidine, methyldopa</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Prazosin</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Propranolol</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Reserpine</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-43">
						<td class="Basic-Table CellOverride-28" />
						<td class="Basic-Table CellOverride-28">
							<p class="table-body"><span class="CharOverride-2">Antidepressants and psychotropic drugs</span></p>
						</td>
						<td class="Basic-Table CellOverride-28" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Amitriptyline, nortriptyline</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Amoxapine, trimipramine</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Clomipramine, desipramine, imipramine</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Diazepam, nitrazepam</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Doxepin</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Phenelzine, tranylcypromine</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Phenothiazines</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-43">
						<td class="Basic-Table CellOverride-28" />
						<td class="Basic-Table CellOverride-28">
							<p class="table-body"><span class="CharOverride-2">Cardiac antiarrhythmia drugs</span></p>
						</td>
						<td class="Basic-Table CellOverride-28" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Amiodarone</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Disopyramide</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Mexiletine</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-43">
						<td class="Basic-Table CellOverride-28" />
						<td class="Basic-Table CellOverride-28">
							<p class="table-body"><span class="CharOverride-2">Parkinson disease medications</span></p>
						</td>
						<td class="Basic-Table CellOverride-28" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Benztropine</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Biperiden</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Procyclidine</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Trihexyphenidyl</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-43">
						<td class="Basic-Table CellOverride-28" />
						<td class="Basic-Table CellOverride-28">
							<p class="table-body"><span class="CharOverride-2">Antiulcer agents</span></p>
						</td>
						<td class="Basic-Table CellOverride-28" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Atropine-like agents</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Metoclopramide, other drugs that decrease gastric motility</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-43">
						<td class="Basic-Table CellOverride-28" />
						<td class="Basic-Table CellOverride-28">
							<p class="table-body"><span class="CharOverride-2">Muscle spasm medications</span></p>
						</td>
						<td class="Basic-Table CellOverride-28" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Cyclobenzaprine</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Methocarbamol</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-43">
						<td class="Basic-Table CellOverride-28" />
						<td class="Basic-Table CellOverride-28">
							<p class="table-body"><span class="CharOverride-2">Decongestants (nonprescription cold remedies)</span></p>
						</td>
						<td class="Basic-Table CellOverride-28" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Ephedrine</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Pseudoephedrine</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-43">
						<td class="Basic-Table CellOverride-28" />
						<td class="Basic-Table CellOverride-28">
							<p class="table-body"><span class="CharOverride-2">Antihistamines</span></p>
						</td>
						<td class="Basic-Table CellOverride-28" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-43">
						<td class="Basic-Table CellOverride-28" />
						<td class="Basic-Table CellOverride-28">
							<p class="table-body"><span class="CharOverride-2">Anesthetics</span></p>
						</td>
						<td class="Basic-Table CellOverride-28" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Bisphosphonates</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Enflurane</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Halothane</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-20" />
						<td class="Basic-Table CellOverride-20">
							<p class="table-indent-1">Nitrous oxide</p>
						</td>
						<td class="Basic-Table CellOverride-20" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-44">
						<td class="Basic-Table CellOverride-29" />
						<td class="Basic-Table CellOverride-29">
							<p class="table-body"><span class="CharOverride-2">Hormonal: estrogen replacement, androgen antagonists</span></p>
						</td>
						<td class="Basic-Table CellOverride-29" />
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer049">
				<div id="_idContainer047" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-7771.png" alt="" />
				</div>
				<div id="_idContainer048" class="Basic-Text-Frame">
					<p class="figure-caption ParaOverride-18"><span class="figure-number">Figure 3-13</span> Silicone punctal plug. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer050" class="Basic-Text-Frame">
			<table id="table010" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-45" />
					<col class="_idGenTableRowColumn-46" />
					<col class="_idGenTableRowColumn-47" />
					<col class="_idGenTableRowColumn-18" />
					<col class="_idGenTableRowColumn-48" />
					<col class="_idGenTableRowColumn-18" />
					<col class="_idGenTableRowColumn-49" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _1-BCSC-table-title" colspan="7">
							<p class="table-title"><span class="table-number">Table 3-9</span> Clinical Summary of the MGD Staging Used to Guide Treatment</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table _3-BCSC-table-column-head">
							<p class="table-column-head">Stage</p>
						</td>
						<td class="Basic-Table _3-BCSC-table-column-head" />
						<td class="Basic-Table _3-BCSC-table-column-head">
							<p class="table-column-head">MGD Grade</p>
						</td>
						<td class="Basic-Table _3-BCSC-table-column-head" />
						<td class="Basic-Table _3-BCSC-table-column-head">
							<p class="table-column-head">Symptoms</p>
						</td>
						<td class="Basic-Table _3-BCSC-table-column-head" />
						<td class="Basic-Table _3-BCSC-table-column-head">
							<p class="table-column-head">Corneal Staining</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-29">
						<td class="Basic-Table _4-BCSC-table-body-first-row">
							<p class="table-body">1</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _4-BCSC-table-body-first-row">
							<p class="table-body">+ (minimally altered expressibility and secretion quality)</p>
						</td>
						<td class="Basic-Table _4-BCSC-table-body-first-row" />
						<td class="Basic-Table _4-BCSC-table-body-first-row">
							<p class="table-body">None</p>
						</td>
						<td class="Basic-Table _4-BCSC-table-body-first-row" />
						<td class="Basic-Table _4-BCSC-table-body-first-row">
							<p class="table-body">None</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-50">
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30">
							<p class="table-body">2</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30" />
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30">
							<p class="table-body">++ (mildly altered expressibility and secretion quality)</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30" />
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30">
							<p class="table-body">Minimal to mild</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30" />
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30">
							<p class="table-body">None to limited</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-51">
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30">
							<p class="table-body">3</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30" />
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30">
							<p class="table-body">+++ (moderately altered expressibility and secretion quality)</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30" />
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30">
							<p class="table-body">Moderate</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30" />
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30">
							<p class="table-body">Mild to moderate; mainly peripheral</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-50">
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30">
							<p class="table-body">4</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30" />
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30">
							<p class="table-body">++++ (severely altered expressibility and secretion quality)</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30" />
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30">
							<p class="table-body">Marked</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30" />
						<td class="Basic-Table _5-BCSC-table-body CellOverride-30">
							<p class="table-body">Marked; central in addition</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-36">
						<td class="Basic-Table _7-BCSC-table-body-last-row CellOverride-30">
							<p class="table-body">“Plus” disease</p>
						</td>
						<td class="Basic-Table _7-BCSC-table-body-last-row CellOverride-30" />
						<td class="Basic-Table _7-BCSC-table-body-last-row CellOverride-30 _idGenCellOverride-1" colspan="5">
							<p class="table-body">Coexisting or accompanying disorders of the ocular surface and/or eyelids</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-44">
						<td class="Basic-Table _8-BCSC-table-note" colspan="7">
							<p class="table-source-note">Reproduced with permission from Nichols KK, Foulks GN, Bron AJ, et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. <span class="CharOverride-3">Invest Ophthalmol Vis Sci.</span> 2011;52(4):1922–1929.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer053">
				<div id="_idContainer051" class="Basic-Text-Frame">
					<table id="table011" class="Basic-Table TableOverride-1">
						<colgroup>
							<col class="_idGenTableRowColumn-52" />
							<col class="_idGenTableRowColumn-38" />
							<col class="_idGenTableRowColumn-53" />
							<col class="_idGenTableRowColumn-38" />
							<col class="_idGenTableRowColumn-54" />
						</colgroup>
						<thead>
							<tr class="Basic-Table _idGenTableRowColumn-5">
								<td class="Basic-Table _1-BCSC-table-title" colspan="5">
									<p class="table-title"><span class="table-number">Table 3-10</span> <span class="CharOverride-3">(continued)</span></p>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-6">
								<td class="Basic-Table _3-BCSC-table-column-head">
									<p class="table-column-head">Stage</p>
								</td>
								<td class="Basic-Table _3-BCSC-table-column-head" />
								<td class="Basic-Table _3-BCSC-table-column-head">
									<p class="table-column-head">Clinical Description</p>
								</td>
								<td class="Basic-Table _3-BCSC-table-column-head" />
								<td class="Basic-Table _3-BCSC-table-column-head">
									<p class="table-column-head">Treatment</p>
								</td>
							</tr>
						</thead>
						<tbody>
							<tr class="Basic-Table _idGenTableRowColumn-55">
								<td class="Basic-Table _4-BCSC-table-body-first-row CellOverride-31 _idGenCellOverride-2">
									<p class="table-body">1</p>
								</td>
								<td class="Basic-Table _4-BCSC-table-body-first-row CellOverride-31 _idGenCellOverride-2" />
								<td class="Basic-Table _4-BCSC-table-body-first-row CellOverride-31 _idGenCellOverride-2">
									<p class="table-body">No <span class="CharOverride-6">symptoms </span>of ocular <br />discomfort, itching, or photophobia</p>
									<p class="table-body"><span class="CharOverride-6">Clinical signs</span> of MGD based on gland expression </p>
									<ul>
										<li class="table-bullet-list">Minimally altered secretions: grade ≥2 to 4</li>
										<li class="table-bullet-list">Expressibility: 1</li>
										<li class="table-bullet-list">No ocular surface <span class="CharOverride-6">staining</span></li>
									</ul>
								</td>
								<td class="Basic-Table _4-BCSC-table-body-first-row CellOverride-31 _idGenCellOverride-2" />
								<td class="Basic-Table _4-BCSC-table-body-first-row CellOverride-31 _idGenCellOverride-2">
									<p class="table-body"><span class="CharOverride-3">Inform</span> patient about MGD, the potential impact of diet, the effect of work/home environments on tear evaporation, and the possible drying effect of certain systemic medications</p>
									<p class="table-body"><span class="CharOverride-3">Consider</span> eyelid hygiene, including warming/expression as described below&#160;(±)</p>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-56">
								<td class="Basic-Table _5-BCSC-table-body CellOverride-32 _idGenCellOverride-3">
									<p class="table-body">2</p>
								</td>
								<td class="Basic-Table _5-BCSC-table-body CellOverride-32 _idGenCellOverride-3" />
								<td class="Basic-Table _5-BCSC-table-body CellOverride-33 _idGenCellOverride-3">
									<p class="table-body">Minimal to mild <span class="CharOverride-6">symptoms</span> of ocular discomfort, itching, or photophobia</p>
									<p class="table-body">Minimal to mild MGD <span class="CharOverride-6">clinical signs</span></p>
									<ul>
										<li class="table-bullet-list">Scattered eyelid margin features</li>
										<li class="table-bullet-list">Mildly altered secretions: <br />grade ≥4 to &lt;8</li>
										<li class="table-bullet-list">Expressibility: 1</li>
										<li class="table-bullet-list">None to limited ocular surface <span class="CharOverride-6">stainin</span><span class="CharOverride-6">g</span>: DEWS grade 0–7; Oxford grade 0–3<span class="CharOverride-7">*</span></li>
									</ul>
								</td>
								<td class="Basic-Table _5-BCSC-table-body CellOverride-33 _idGenCellOverride-3" />
								<td class="Basic-Table _5-BCSC-table-body CellOverride-34 _idGenCellOverride-3">
									<p class="table-body"><span class="CharOverride-3">Advise</span> patient on improving ambient humidity, optimizing workstations, and increasing dietary omega-3 fatty acid intake (±)</p>
									<p class="table-body"><span class="CharOverride-3">Institute</span> eyelid hygiene with eyelid warming (a minimum of 4 minutes, once or twice daily) followed by moderate to firm massage and expression of MG secretions (+)</p>
									<p class="table-body"><span class="CharOverride-3">All the above, plus</span> (±)</p>
									<ul>
										<li class="table-bullet-list">Artificial lubricants (for frequent use, nonpreserved preferred)</li>
										<li class="table-bullet-list">Topical azithromycin</li>
										<li class="table-bullet-list">Topical emollient lubricant or liposomal spray</li>
										<li class="table-bullet-list">Consider oral tetracycline derivatives</li>
									</ul>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-57">
								<td class="Basic-Table _5-BCSC-table-body CellOverride-35">
									<p class="table-body">3</p>
								</td>
								<td class="Basic-Table _5-BCSC-table-body CellOverride-35" />
								<td class="Basic-Table _5-BCSC-table-body CellOverride-35">
									<p class="table-body">Moderate <span class="CharOverride-6">symptoms </span>of ocular discomfort, itching, or photophobia with limitation of activities</p>
									<p class="table-body">Moderate MGD <span class="CharOverride-6">clinical signs</span></p>
									<ul>
										<li class="table-bullet-list"><span class="math">↑</span> Eyelid margin features: plugging, vascularity</li>
										<li class="table-bullet-list">Moderately altered secretions: grade ≥8 to &lt;13</li>
										<li class="table-bullet-list">Expressibility: 2</li>
										<li class="table-bullet-list">Mild to moderate conjunctival and peripheral corneal <span class="CharOverride-6">staining,</span> often inferior: DEWS grade 8–23; Oxford grade 4–10</li>
									</ul>
								</td>
								<td class="Basic-Table _5-BCSC-table-body CellOverride-35" />
								<td class="Basic-Table _5-BCSC-table-body CellOverride-35">
									<p class="table-body"><span class="CharOverride-3">All the above, plus</span></p>
									<ul>
										<li class="table-bullet-list">Oral tetracycline derivatives (+)</li>
										<li class="table-bullet-list">Lubricant ointment at bedtime (±)</li>
										<li class="table-bullet-list">Anti-inflammatory therapy for dry eye as indicated (±)</li>
									</ul>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-58">
								<td class="Basic-Table _5-BCSC-table-body CellOverride-30">
									<p class="table-body">4</p>
								</td>
								<td class="Basic-Table _5-BCSC-table-body CellOverride-30" />
								<td class="Basic-Table _5-BCSC-table-body CellOverride-30">
									<p class="table-body">Marked <span class="CharOverride-6">symptoms</span> of ocular discomfort, itching, or photophobia with definite limitation of activities</p>
									<p class="table-body">Severe MGD <span class="CharOverride-6">clinical signs </span></p>
									<ul>
										<li class="table-bullet-list"><span class="math">↑</span> Eyelid margin features: dropout, displacement</li>
										<li class="table-bullet-list">Severely altered secretions: grade&#160;≥13</li>
										<li class="table-bullet-list">Expressibility: 3</li>
										<li class="table-bullet-list">Increased conjunctival and corneal <span class="CharOverride-6">staining,</span> including central staining: DEWS grade 24–33; Oxford grade 11–15</li>
										<li class="table-bullet-list"><span class="math">↑</span> Signs of inflammation: ≥moderate conjunctival hyperemia, phlyctenules</li>
									</ul>
								</td>
								<td class="Basic-Table _5-BCSC-table-body CellOverride-30" />
								<td class="Basic-Table _5-BCSC-table-body CellOverride-30">
									<p class="table-body"><span class="CharOverride-3">All the above, plus</span></p>
									<ul>
										<li class="table-bullet-list">Anti-inflammatory therapy for dry eye (+)</li>
									</ul>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-50">
								<td class="Basic-Table _4-BCSC-table-body-first-row CellOverride-30 _idGenCellOverride-4" rowspan="2">
									<p class="table-body">“Plus” disease</p>
								</td>
								<td class="Basic-Table _4-BCSC-table-body-first-row CellOverride-30 _idGenCellOverride-4" rowspan="2" />
								<td class="Basic-Table _4-BCSC-table-body-first-row CellOverride-30 _idGenCellOverride-1" colspan="3">
									<p class="table-body">Specific conditions occurring at any stage and requiring treatment. May be causal of, or secondary to, MGD or may occur incidentally</p>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-59">
								<td class="Basic-Table _5-BCSC-table-body CellOverride-36 _idGenCellOverride-4">
									<p class="table-numbered-list">1.&#9;Exacerbated inflammatory ocular surface disease</p>
									<p class="table-numbered-list">2.&#9;Mucosal keratinization</p>
									<p class="table-numbered-list">3.&#9;Phlyctenular keratitis</p>
									<p class="table-numbered-list">4.&#9;Trichiasis (eg, in cicatricial conjunctivitis, mucous membrane pemphigoid)</p>
									<p class="table-numbered-list">5.&#9;Chalazion</p>
									<p class="table-numbered-list">6.&#9;Anterior blepharitis</p>
									<p class="table-numbered-list">7.&#9;<span class="CharOverride-3">Demodex</span>-related anterior blepharitis, with cylindrical dandruff</p>
								</td>
								<td class="Basic-Table _5-BCSC-table-body CellOverride-36 _idGenCellOverride-4" />
								<td class="Basic-Table _5-BCSC-table-body CellOverride-36 _idGenCellOverride-4">
									<p class="table-numbered-list">1.&#9;Pulsed soft steroid as indicated</p>
									<p class="table-numbered-list">2.&#9;Bandage contact lens/scleral contact lens</p>
									<p class="table-numbered-list">3.&#9;Steroid therapy</p>
									<p class="table-numbered-list">4.&#9;Epilation, electrolysis using radiofrequency</p>
									<p class="table-numbered-list">5.&#9;Intralesional steroid or excision</p>
									<p class="table-numbered-list">6.&#9;Topical antibiotic or antibiotic/steroid</p>
									<p class="table-numbered-list">7.&#9;Tea tree oil scrubs</p>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-60">
								<td class="Basic-Table _8-BCSC-table-note" colspan="5">
									<p class="table-footnote--no-indent-">DEWS = Dry Eye Workshop; MG = meibomian gland; MGD = meibomian gland dysfunction.</p>
									<p class="table-footnote--no-indent-"><span class="CharOverride-3">Meibum quality</span> is assessed in each of eight glands of the central third of the lower eyelid on a scale of 0 to 3 for each gland: 0, clear; 1, cloudy; 2, cloudy with debris (granular); and 3, thick, like toothpaste (total score range, 0–24). <span class="CharOverride-3">Expressibility</span> is assessed on a scale of 0 to 3 in five glands in the lower or upper eyelid, according to the number of glands expressible: 0, all glands; 1, three to four glands; 2, one to two glands; and 3, no glands. <span class="CharOverride-3">Staining scores</span> are obtained by summing the scores of the exposed cornea and conjunctiva. Oxford staining score range, 1–15; DEWS staining score range, 0–33.</p>
									<p class="table-footnote--no-indent-"><span class="table-superscript-note-ast-">*</span>Oxford grade: see Anthony.bron@eye.ex.ac.uk.</p>
									<p class="table-source-note ParaOverride-10">Modified with permission from Nichols KK, Foulks GN, Bron AJ, et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. <span class="CharOverride-3">Invest Ophthalmol Vis Sci.</span> 2011;52(4):1922–1929.</p>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-43">
								<td class="Basic-Table _8-BCSC-table-note" colspan="5" />
							</tr>
						</tbody>
					</table>
				</div>
				<div id="_idContainer052" class="Basic-Text-Frame _idGenObjectStyleOverride-2">
					<p class="table-title">Treatment Algorithm for Meibomian Gland Dysfunction</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer056">
				<div id="_idContainer054" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-2845.png" alt="" />
				</div>
				<div id="_idContainer055" class="Basic-Text-Frame">
					<p class="figure-caption ParaOverride-18"><span class="figure-number">Figure 3-14</span> Stromal keratitis associated with rosacea.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer059">
				<div id="_idContainer057" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-9256.png" alt="" />
				</div>
				<div id="_idContainer058" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 3-15</span> <span class="figure-caption-bold">A,</span>&#160;Rosacea-&#173;associated marginal keratitis with possible episcleritis. <span class="figure-caption-bold">B,</span>&#160;Corneal neovascularization and scarring associated with rosacea. <span class="figure-source-note">(Courtesy of Mark Mannis, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer062">
				<div id="_idContainer060" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-9259.jpg" alt="" />
				</div>
				<div id="_idContainer061" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 3-16</span> Facial characteristics of moder-<br />ate acne rosacea, including facial erythema, papules, and rhinophyma. <span class="figure-source-note">(Courtesy of Robert&#160;S. Feder, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer065">
				<div id="_idContainer063" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-9260.png" alt="" />
				</div>
				<div id="_idContainer064" class="Basic-Text-Frame">
					<p class="figure-caption ParaOverride-18"><span class="figure-number">Figure 3-17</span> Blepharitis schematic.</p>
				</div>
			</div>
		</div>
		<div id="_idContainer066" class="Basic-Text-Frame">
			<table id="table012" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-61" />
					<col class="_idGenTableRowColumn-62" />
					<col class="_idGenTableRowColumn-63" />
					<col class="_idGenTableRowColumn-62" />
					<col class="_idGenTableRowColumn-64" />
					<col class="_idGenTableRowColumn-62" />
					<col class="_idGenTableRowColumn-25" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style CellOverride-1 _idGenCellOverride-1" colspan="7">
							<p class="table-title"><span class="table-number">Table 3-11</span> Types of Blepharitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-10">
						<td class="No-Table-Style CellOverride-37" />
						<td class="No-Table-Style CellOverride-37" />
						<td class="No-Table-Style CellOverride-37">
							<p class="table-column-head">Staphylococcal</p>
						</td>
						<td class="No-Table-Style CellOverride-37" />
						<td class="No-Table-Style CellOverride-37">
							<p class="table-column-head">Meibomian Gland</p>
							<p class="table-column-head">Dysfunction</p>
						</td>
						<td class="No-Table-Style CellOverride-37" />
						<td class="No-Table-Style CellOverride-37">
							<p class="table-column-head">Seborrheic</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-29">
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body"><span class="CharOverride-2">Location</span></p>
						</td>
						<td class="No-Table-Style CellOverride-3" />
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Anterior eyelid margin</p>
						</td>
						<td class="No-Table-Style CellOverride-3" />
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Posterior eyelid margin</p>
						</td>
						<td class="No-Table-Style CellOverride-3" />
						<td class="No-Table-Style CellOverride-3">
							<p class="table-body">Anterior eyelid margin</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style CellOverride-4">
							<p class="table-body"><span class="CharOverride-2">Loss and whitening<br />of eyelashes</span></p>
						</td>
						<td class="No-Table-Style CellOverride-4" />
						<td class="No-Table-Style CellOverride-4">
							<p class="table-body">Varying degrees</p>
						</td>
						<td class="No-Table-Style CellOverride-4" />
						<td class="No-Table-Style CellOverride-38">
							<p class="table-body">(–)</p>
						</td>
						<td class="No-Table-Style CellOverride-4" />
						<td class="No-Table-Style CellOverride-4">
							<p class="table-body">Rare</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-65">
						<td class="No-Table-Style CellOverride-39">
							<p class="table-body"><span class="CharOverride-2">Eyelid crusting</span></p>
						</td>
						<td class="No-Table-Style CellOverride-39" />
						<td class="No-Table-Style CellOverride-39">
							<p class="table-body">Hard, fibrinous scales; hard, matted crusts (often accompany ulcerative form)</p>
						</td>
						<td class="No-Table-Style CellOverride-39" />
						<td class="No-Table-Style CellOverride-40">
							<p class="table-body">+/–</p>
						</td>
						<td class="No-Table-Style CellOverride-39" />
						<td class="No-Table-Style CellOverride-39">
							<p class="table-body">Oily or greasy</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-66">
						<td class="No-Table-Style CellOverride-39">
							<p class="table-body"><span class="CharOverride-2">Eyelid ulceration</span></p>
						</td>
						<td class="No-Table-Style CellOverride-39" />
						<td class="No-Table-Style CellOverride-39">
							<p class="table-body">Occasional</p>
						</td>
						<td class="No-Table-Style CellOverride-39" />
						<td class="No-Table-Style CellOverride-40">
							<p class="table-body">(–)</p>
						</td>
						<td class="No-Table-Style CellOverride-39" />
						<td class="No-Table-Style CellOverride-41">
							<p class="table-body">(–)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-65">
						<td class="No-Table-Style CellOverride-39">
							<p class="table-body"><span class="CharOverride-2">Conjunctivitis</span></p>
						</td>
						<td class="No-Table-Style CellOverride-39" />
						<td class="No-Table-Style CellOverride-39">
							<p class="table-body">Papillary (occasionally<br />with mucopurulent discharge)</p>
						</td>
						<td class="No-Table-Style CellOverride-39" />
						<td class="No-Table-Style CellOverride-39">
							<p class="table-body">Mild to moderate injection, papillary tarsal reaction</p>
						</td>
						<td class="No-Table-Style CellOverride-39" />
						<td class="No-Table-Style CellOverride-39">
							<p class="table-body">Mild injection, follicular or papillary tarsal reaction</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-65">
						<td class="No-Table-Style CellOverride-39">
							<p class="table-body"><span class="CharOverride-2">Keratitis</span></p>
						</td>
						<td class="No-Table-Style CellOverride-39" />
						<td class="No-Table-Style CellOverride-39">
							<p class="table-body">Inferior PEE, marginal infiltrates, vascularization, phlyctenulosis</p>
						</td>
						<td class="No-Table-Style CellOverride-39" />
						<td class="No-Table-Style CellOverride-39">
							<p class="table-body">Inferior PEE, marginal infiltrates, vascular pannus</p>
						</td>
						<td class="No-Table-Style CellOverride-39" />
						<td class="No-Table-Style CellOverride-39">
							<p class="table-body">Inferior PEE</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style CellOverride-42">
							<p class="table-body"><span class="CharOverride-2">Rosacea</span></p>
						</td>
						<td class="No-Table-Style CellOverride-42" />
						<td class="No-Table-Style CellOverride-42">
							<p class="table-body ParaOverride-18">(–)</p>
						</td>
						<td class="No-Table-Style CellOverride-42" />
						<td class="No-Table-Style CellOverride-42">
							<p class="table-body">Common</p>
						</td>
						<td class="No-Table-Style CellOverride-42" />
						<td class="No-Table-Style CellOverride-42">
							<p class="table-body">Less common</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-40">
						<td class="No-Table-Style CellOverride-43" colspan="7">
							<p class="table-footnote">PEE = punctate epithelial erosions.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer069">
				<div id="_idContainer067" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-9261.png" alt="" />
				</div>
				<div id="_idContainer068" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 3-18</span> <span class="figure-caption-bold">A,</span>&#160;Eyelash sleeves typical of demodicosis. <span class="figure-caption-bold">B,</span>&#160;Staphylococcal blepharitis. <span class="figure-source-note">(Part A courtesy of Robert S. Feder, MD; part B courtesy of Robert W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer072">
				<div id="_idContainer070" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-7773.png" alt="" />
				</div>
				<div id="_idContainer071" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 3-19</span> Staphyloccocal marginal corneal infiltrates are typically oval, white opacities; usually, there is a clear zone between the lesions and the limbus. <span class="figure-source-note">(Courtesy of David Rootman, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer075">
				<div id="_idContainer073" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-9264.png" alt="" />
				</div>
				<div id="_idContainer074" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 3-20</span> Phlyctenule. <span class="figure-caption-bold">A,</span>&#160;Confluent phlyctenules secondary to staphylococcal blepharitis. <span class="figure-caption-bold">B,</span>&#160;Recurrent phlyctenular involvement may result in fibrovascular scarring that progresses across the cornea and into the visual axis. <span class="figure-source-note">(Part&#160;B courtesy of Robert&#160;S. Feder, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer078">
				<div id="_idContainer076" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 3-21</span> Hordeolum. <span class="figure-source-note">(Courtesy of Vincent&#160;P. deLuise, MD.)</span></p>
				</div>
				<div id="_idContainer077" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch03_p045-078-web-resources/image/AAX-2848.jpg" alt="" />
				</div>
			</div>
		</div>
	</body>
</html>
